The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury Authors: Changhong Jiang, Chao Liu, Xuan He, Yuchen Guo, Jing Zhang Published: 2026 ABSTRACT AbstractRenal ischemia-reperfusion injury (RIRI) is one of the main causes of acute kidney injury (AKI), and its pathological mechanism is complex, mainly involving multiple pathological processes such as oxidative stress outbreak, uncontrolled inflammatory response, abnormal cell apoptosis, and microcirculatory disorders. Currently, there is a lack of efficient and accurate diagnosis and treatment strategies in clinical practice. As a cross discipline integrating nanomaterials, medicine and biology, nanomedicine has shown unique advantages and broad application prospects in the diagnosis and treatment field of RIRI in recent years. Its core carriers include inorganic nanoparticles, polymeric nanoparticles, nanoenzymes, extracellular vesicles, cell membrane camouflage nanoparticles and injectable nanohydrogels. The diagnosis and treatment system based on nanomedicine can breakthrough the limitations of traditional diagnosis and treatment models, and play an important role in early accurate diagnosis, targeted drug delivery, precise treatment of lesion sites, and prolonged drug circulation time in RIRI. It effectively solves pain points such as strong toxicity, short circulation time, and poor targeting of single drugs. However, the specific mechanism of action of nanomedicine in RIRI has not been fully elucidated, and issues such as the biosafety, in vivo metabolic patterns, and clinical translation bottlenecks of nanomedicine still need to be urgently addressed. This review aims to systematically review the application and mechanism research progress of nanomedicine in RIRI, briefly explain the core pathological mechanism of RIRI, focus on the application effects and mechanisms of nanomedicine systems composed of different types of nanocarriers in RIRI diagnosis and treatment, summarize the current research challenges and look forward to future development directions, providing theoretical basis and practical reference for in-depth research, technological breakthroughs, and clinical translation of nanomedicine in the field of RIRI. Introduction Renal ischemia-reperfusion injury (RIRI) refers to the pathological process in which renal blood flow is temporarily interrupted, causing ischemic and hypoxic damage to the kidneys. When blood flow is restored and reperfusion occurs, not only does it fail to alleviate the damage, but it further exacerbates the damage to renal tissue.1 As the main cause of acute kidney injury (AKI), RIRI widely occurs in clinical scenarios such as kidney transplantation, hemorrhagic shock, cardiac arrest resuscitation, and renal artery intervention surgery. In severe cases, it can progress to chronic kidney disease or even end-stage renal disease, posing great challenges to clinical diagnosis and treatment and increasing the burden on social healthcare. The pathophysiological mechanisms of RIRI are complex and interrelated, including overactivation of oxidative stress response, infiltration of inflammatory cells and release of inflammatory factors, calcium overload, mitochondrial dysfunction, and necrosis/apoptosis of renal tubular epithelial cells. These pathological factors work together to ultimately lead to the destruction of renal tissue structure and a sharp decline in renal function.2 At present, the clinical treatment of RIRI is still mainly based on symptomatic supportive therapy. Although a single drug has shown certain renal protection effects in animal experiments, it is difficult to achieve clinical translation due to limitations such as poor targeting, short circulation time, low bioavailability, and obvious toxic side effects.3 In addition, there is a lack of systematic research on the interaction between a single drug and the complex pathological microenvironment and other molecular mechanisms of the body, such as sex hormone regulation. Its applicability and safety in human clinical practice still need to be further validated, and there is an urgent need to develop new and efficient diagnostic and therapeutic strategies. Nanomedicine uses nanomedicine as the core carrier and through precise regulation of the particle size, morphology, and surface functionalization modification of nanocarriers, constructs a nanomedicine system that combines diagnostic and therapeutic functions. It can achieve the integration of “diagnosis treatment monitoring” and provide a new approach for precise diagnosis and treatment of RIRI. Compared with traditional diagnosis and treatment models, nanomedicine systems have unique advantages: precise enrichment of kidney injury sites can be achieved through surface targeted modification, reducing damage to normal tissues; extend drug circulation time and improve bioavailability through sustained-release design. Some nanomedicines, such as nanoenzymes and cell membrane disguised nanoparticles, can also directly participate in pathological microenvironment regulation and exert multiple renal protective effects.4 The long-term metabolism and potential nephrotoxicity of some traditional drugs in the body are not fully understood, for example, metformin has been shown to have dose-dependent nephrotoxicity in RIRI, which may exacerbate the severity of acute kidney injury.5 Nanocarriers can significantly enhance biocompatibility through surface functionalization modification, achieving targeted drug delivery and precise drug release, effectively reducing drug toxicity and side effects, while avoiding clearance by the body’s immune system, further optimizing treatment efficacy.6 This article focuses on the core theme of “the application prospects of nanomedicine in RIRI” and systematically reviews the research status and progress of nanomedicine in RIRI diagnosis and treatment. Firstly, briefly explain the core pathological mechanism of RIRI, laying a theoretical foundation for the subsequent application analysis of nanomedicine. Secondly, the focus is on analyzing the application effects, mechanisms, and advantages of nanomedicine systems composed of different types of nanocarriers in RIRI. Finally, summarize the core challenges faced by nanomedicine in RIRI research, such as unclear mechanisms, biosafety, and difficulties in clinical translation, and look forward to future development directions, in order to provide theoretical basis and technical support for the development of new RIRI diagnosis and treatment strategies in clinical practice, and promote the standardized development and clinical translation of nanomedicine in the field of kidney disease diagnosis and treatment. Pathogenesis of Renal Ischemia-Reperfusion Injury The injury process of RIRI is divided into ischemia phase and reperfusion phase. The ischemia phase mainly causes renal tissue hypoxia and energy metabolism disorders, while the rapid recovery of oxygen during reperfusion phase triggers severe secondary damage, activates multiple pathological pathways, and forms a vicious cycle, ultimately leading to a large number of deaths of epithelial cells on the renal tubules, structural damage to renal tissue, and irreversible damage to renal function. The core pathological mechanisms are interconnected and progressively amplified, forming a complete injury network of RIRI (Figure 1). Figure 1Cascade pathological process of renal ischemia-reperfusion injury: Renal ischemia triggers mitochondrial dysfunction, endoplasmic reticulum stress, cellular calcium overload, and microcirculation disorders, laying the pathological foundation for reperfusion injury. After the restoration of blood flow, ROS outbreak, neutrophil infiltration, and IL-1 mediated inflammatory response mutually promote each other, further exacerbating renal injury; Inflammation and oxidative stress, in turn, exacerbate ischemic injury, forming a vicious cycle. Continuous pathological stimulation ultimately leads to abnormal repair of renal tubules and interstitial fibrosis, progressing to chronic kidney disease.The image illustrates the cascade pathological process of renal ischemia-reperfusion injury leading to chronic kidney disease. It is divided into three stages: ischemia injury stage, reperfusion injury stage and chronic kidney disease. In the ischemia injury stage, mitochondrial dysfunction, endoplasmic reticulum stress, cellular calcium overload and microcirculatory disorder are depicted. An arrow leads to the reperfusion injury stage, showing reactive oxygen species outbreak, neutrophil infiltration and interleukin 1 mediated inflammation response. Another arrow points to chronic kidney disease, highlighting abnormal renal tubular repair and renal interstitial fibrosis. The diagram visually represents the interconnected pathological mechanisms and progression of renal injury.Renal injury stages to chronic kidney disease: cellular dysfunction, inflammation. Cascade pathological process of renal ischemia-reperfusion injury: Renal ischemia triggers mitochondrial dysfunction, endoplasmic reticulum stress, cellular calcium overload, and microcirculation disorders, laying the pathological foundation for reperfusion injury. After the restoration of blood flow, ROS outbreak, neutrophil infiltration, and IL-1 mediated inflammatory response mutually promote each other, further exacerbating renal injury; Inflammation and oxidative stress, in turn, exacerbate ischemic injury, forming a vicious cycle. Continuous pathological stimulation ultimately leads to abnormal repair of renal tubules and interstitial fibrosis, progressing to chronic kidney disease. Cellular Calcium Overload Calcium overload is one of the most core-initiating mechanisms in the early stage of RIRI, which runs through the entire process from ischemia to reperfusion and rapidly amplifies, ultimately driving apoptosis, programmed necrosis, and pyroptosis of renal tubular epithelial cells, resulting in irreversible renal function damage. Renal ischemia and hypoxia can lead to depletion of cellular ATP synthesis, resulting in an imbalance of the calcium ion homeostasis regulatory system. Specifically, this is manifested as an increase in the influx of extracellular calcium ions through the cell membrane calcium channels, inhibition of the calcium efflux function of the cell membrane Ca2+ ATPase, and large release of calcium ions from organelles such as the endoplasmic reticulum and mitochondria. The restoration of oxygen supply during the reperfusion phase induces reverse transport of sodium calcium exchangers (NCX), further exacerbating the influx of extracellular calcium ions and inducing dual-calcium overload in the cytoplasm and mitochondria.7 Excessive calcium ions over activate calcium-dependent proteases, nucleases, and phospholipases, directly damaging the cytoskeleton, cell membrane, and nucleic acid structure. On the other hand, mitochondrial matrix calcium overload can damage the abnormal opening of mitochondrial permeability transition pores (mPTP), promote the release of apoptotic factors such as cytochrome C and apoptosis-inducing factor (AIF), activate the caspase cascade reaction, and directly initiate endogenous apoptotic pathways. Meanwhile, cytoplasmic high calcium can activate downstream inflammatory signaling pathways such as NF-κB and MAPK, upregulate pro-apoptotic protein Bax and downregulate anti-apoptotic protein Bcl-2, further amplifying apoptotic signals.8 In addition, calcium overload can serve as an upstream key signal, directly activating the assembly and activation of NADPH oxidase complex, inducing a large amount of non-mitochondrial ROS generation, while exacerbating mitochondrial oxidative stress damage, forming a vicious cycle of “calcium overload oxidative stress calcium homeostasis further imbalance”, synergistically mediating apoptosis, programmed necrosis, and ferroptosis of renal tubular epithelial cells, and promoting the sustained progression of renal ischemia-reperfusion injury.9 Mitochondrial Dysfunction Mitochondrial dysfunction is the core pathological mechanism in the RIRI process. During the ischemia and hypoxia stage of renal tissue, the activity of mitochondrial electron transfer chain (ETC) complexes I and III in renal tubular epithelial cells is significantly inhibited, electron transfer is blocked, and a large amount of leakage occurs, making it impossible to bind with oxygen molecules normally to generate water, which then reacts abnormally with intracellular oxygen to generate a large amount of reactive oxygen species (ROS) such as superoxide anions and hydrogen peroxide. At the same time, ischemia leads to compensatory activation of cellular anaerobic metabolism, resulting in extremely low efficiency of glycolysis production, which cannot compensate for the energy gap caused by mitochondrial aerobic respiration arrest, and initially leads to depletion of intracellular ATP reserves. The reperfusion stage of blood brings a large amount of oxygen, which triggers the “oxygen explosion” effect, further increasing ROS generation. Excessive ROS can directly attack mitochondrial membrane phospholipids, respiratory-chain proteins, and mitochondrial DNA, completely destroying mitochondrial structural integrity and physiological functions. The mitochondrial membrane potential collapse and abnormal electron transport-chain function will further exacerbate the massive release of ROS,10 continuously inhibiting the oxidative phosphorylation process, blocking the core pathway of ATP synthesis, exacerbating ATP progressive depletion, and forming a vicious cycle of oxidative stress mitochondrial damage energy depletion.11 Continuous accumulation of ROS and depletion of ATP will further disrupt the energy-dependent homeostasis of intracellular calcium pumps and ion channels, leading to increased calcium ion influx and hindered efflux, resulting in an imbalance of calcium ion homeostasis. At the same time, energy deficiency can release the inhibitory state of the cell apoptosis pathway, promote the activation of Bax/Bak pro-apoptotic proteins, release of apoptosis-related factors such as cytochrome C, initiate programmed cell death of renal tubular epithelial cells, and significantly aggravate renal tubular epithelial cell damage.12 From this, it can be seen that mitochondrial dysfunction is a key hub mediating oxidative stress and programmed cell death. ROS abnormal burst and ATP depletion are the core molecular events of mitochondrial injury mediated RIRI. At the same time, oxidative stress and mitochondrial dysfunction are mutually induced and amplified, jointly promoting the pathological process of RIRI. Mitochondrial oxidative phosphorylation damage is the core initiating and amplifying process of various kidney injuries such as renal ischemia-reperfusion, drug nephrotoxicity, metabolic nephropathy, etc. Through ATP depletion, ROS burst, calcium overload, cell apoptosis/iron death, inflammatory activation, and fibrosis remodeling, it runs through the entire process of acute kidney injury occurrence, progression, and transition to chronic kidney disease.13 Targeted restoration of OXPHOS homeostasis and protection of mitochondrial function are important targets for the prevention and treatment of kidney injury. Oxidative Stress NADPH oxidase is the main source of non-mitochondrial reactive oxygen species (ROS) in RIRI, and its abnormal activation is an important upstream mechanism of oxidative stress outbreak. Under RIRI stimulation, signals such as inflammatory factors, calcium overload, and TLR receptor activation can promote the translocation of NADPH oxidase subunits from the cytoplasm to the cell membrane, assemble with membrane-bound subunits to form a complete active enzyme complex, and relieve resting state inhibition. The activated NADPH oxidase uses cytoplasmic NADPH as an electron donor, mediates electron transmembrane transfer, and catalyzes single electron reduction of oxygen molecules, generating a large amount of superoxide anions. After being converted into hydrogen peroxide by superoxide dismutase, it can further generate more toxic ROS such as hydroxyl radicals. ROS can also activate NADPH oxidase in reverse to form a positive feedback loop, causing sustained excessive accumulation of ROS.14 ROS derived from NADPH oxidase can directly damage mitochondrial membranes, disrupt respiratory-chain function, induce massive release of mitochondrial ROS, and synergistically exacerbate oxidative damage to renal tubular epithelial cells in conjunction with mitochondrial dysfunction. On the other hand, DNA damage can be directly caused by base oxidation and DNA strand breaks, which in turn can further disrupt mitochondrial structure and function, as well as the body’s antioxidant system, promoting ROS generation. This forms a bidirectional vicious cycle of oxidative stress DNA damage, jointly driving the death of renal tubular cells and renal tissue damage, and promoting the progress of RIRI.11,15 Endoplasmic Reticulum Stress Continuous oxidative damage and mitochondrial dysfunction can disrupt the homeostasis of the endoplasmic reticulum, leading to the accumulation of misfolded and unfolded proteins, which in turn trigger endoplasmic reticulum stress response (ERS). Moderate endoplasmic reticulum stress can activate the unfolded protein response (UPR) pathway, upregulate the expression of molecular chaperones to repair protein folding, clear abnormal proteins, and exert cellular protective compensatory effects. Long term excessive endoplasmic reticulum stress can shift UPR from adaptive protection to pro-injury mode.16 On the one hand, it continues to exacerbate oxidative stress and calcium homeostasis imbalance, further damaging mitochondrial structure and function, forming a vicious cycle of mitochondrial endoplasmic reticulum interaction damage. On the other hand, over activated core pathways such as PERK, IRE1 α, and ATF6 can directly upregulate apoptosis key molecules such as CHOP and Caspase 12, activate mitochondrial dependent and non-dependent apoptosis signaling pathways, induce apoptosis, pyroptosis, or necrosis of renal tubular epithelial cells, and ultimately mediate renal tubular structural and functional damage, deeply participating in the pathological process of RIRI.14 Inflammatory Response The overactivation of the inflammatory cascade is the most core pathological feature of RIRI during reperfusion, and the interaction and activation of multiple inflammatory signaling pathways, inflammatory cell infiltration, and cytokine cascade reactions are the key mechanisms mediating the sustained amplification and prolonged aggravation of RIRI inflammatory damage. Among them, NF-κB is the core hub pathway that regulates the inflammatory response of RIRI. Ischemia reperfusion stimulation can induce phosphorylation and degradation of IκB, promote nuclear translocation of p65/p50, and drive the massive release of various pro-inflammatory and chemokines such as TNF-α, IL-1β, IL-6, etc.17 At the same time, the TLR4, MAPK, and PI3K/AKT pathways can regulate and promote NF-κB activation upstream. The NLRP3 inflammasome can also form a positive feedback loop with NF-κB, further amplifying cell apoptosis and inflammatory storms. Multiple pathways work together to mediate the early initiation, mid-term amplification, and sustained damage of RIRI inflammatory response throughout the process.18 Based on the activation of inflammatory pathways, RIRI can induce early activation of renal microvascular endothelial cells and upregulate the expression of adhesion molecules and chemokines,19 thereby mediating neutrophil adhesion, migration, and renal tissue infiltration. Activated neutrophils can release a large amount of ROS, hydrolytic enzymes, and pro-inflammatory mediators, directly damaging renal tubular epithelial cells, while further activating endothelial cells and renal intrinsic cells, forming a bidirectional injury loop. The transient burst of ROS and damage associated molecular patterns (DAMPs) released by necrotic cells during reperfusion will continue to activate the intrinsic cells and infiltrating immune cells of the kidney, initiating a cascade cascade reaction of inflammatory factors. Early secreted pro-inflammatory factors such as TNF-α and IL-1β can further induce downstream inflammatory mediators such as IL-6 and IL-18 to be continuously released from renal tubular epithelial cells, mesangial cells, and macrophages, recruiting more peripheral inflammatory cells to infiltrate, ultimately forming a pathological process of “ROS DAMPs activation → inflammatory pathway activation → cytokine cascade amplification → inflammatory cell infiltration → oxidative inflammatory vicious cycle”, inducing renal microcirculation disorders, no reflow phenomenon, and irreversible damage to renal tubular structure, which continues to aggravate renal function damage.20–22 From this, it can be seen that targeting the inhibition of core inflammatory pathways, such as NF-κB, blocking the uncontrolled cascade of cytokines and the vicious cycle of inflammation, is an important research target for reducing secondary inflammatory damage in RIRI and achieving renal protection. Cell Death The duration of ischemia switches cell death modes step by regulating cellular ATP levels, oxidative stress intensity, calcium overload, and mitochondrial function. During transient ischemia, there is mild energy depletion, mainly through protective autophagy, accompanied by only a small amount of apoptosis. Under moderate ischemia, ATP significantly decreases, mitochondrial damage worsens, apoptosis becomes the main mode of death, and autophagic death and ferroptosis occur simultaneously. During persistent ischemia, lipid peroxidation erupts and ferroptosis dominates. During severe ischemia, energy is completely depleted, ultimately leading to necrosis and necrosis, triggering severe inflammatory damage.23 Necrosis, apoptosis, and autophagy are the core mechanisms mediating damage to renal tubular epithelial cells, regulated by signaling pathways such as calcium overload, oxidative stress, and inflammation. There are significant differences in their occurrence characteristics and damage effects, and they are interrelated, which is the key to continuously exacerbating renal injury. Necrosis (mainly procedural necrosis) is the dominant lethal mode of long-term IRI. It often erupts in large quantities during the late stage of reperfusion, relying on the activation of the RIPK1/RIPK3/MLKL pathway. The cell membrane ruptures and releases a large number of damage-related molecular patterns, triggering severe inflammatory reactions and causing irreversible structural damage to renal tubules, which is the main cause of renal function deterioration.24,25 Apoptosis is mainly mitochondrial dependent endogenous apoptosis, which belongs to controllable programmed cell death. It can be activated in the early stage of reperfusion and continues to be expressed at a low level in the later stage. Initiated by mitochondrial calcium overload and abnormal mPTP opening, the caspase cascade is activated through the release of CytC and AIF, as well as Bax/Bcl-2 imbalance. Cells are cleared in the form of apoptotic bodies, with no leakage of contents. The inflammatory response is mild, and the degree of damage is much weaker than necrosis, making it an auxiliary mode of cell death.26,27 Autophagy has obvious spatiotemporal dependent bidirectional regulatory characteristics. During short-term ischemia, moderate autophagy can clear damaged mitochondria, alleviate calcium overload and oxidative stress, inhibit cell death, and exert renal protection. However, prolonged ischemia-reperfusion can lead to excessive activation of autophagy, degradation of key cellular structural proteins, induction of autophagic cell death, and amplification of oxidative stress and inflammatory response, synergistically exacerbating renal injury.28,29 Long term IRI promotes the synergistic effect of necrosis and apoptosis, exacerbating extensive cellular damage. Excessive autophagy can further amplify signals of necrosis and apoptosis, and the inflammatory storm induced by necrosis can reverse activate the cell death pathway, resulting in multiple injuries and ultimately promoting the sustained progression of RIRI. Renal Microcirculation Disorder Microcirculatory perfusion disorders occur after renal ischemia-reperfusion: after endothelial injury, a large amount of vasoconstrictor substances are released, which in turn leads to renal vascular spasm. At the same time, inflammatory cell adhesion and aggregation, microthrombosis formation, and increased capillary permeability collectively lead to renal tissue ischemia without reperfusion phenomenon. Microcirculatory disorders further exacerbate renal ischemia and hypoxia, amplify oxidative stress, inflammatory infiltration, and cell apoptosis, forming a cascade of damage cascade effects, and continuously worsening renal parenchymal damage.30 Progress and Transformation from AKI to CKD After RIRI, abnormal repair of renal tubular epithelium, persistent inflammatory infiltration, and chronic oxidative stress jointly drive the activation of renal interstitial fibroblasts and excessive deposition of extracellular matrix, ultimately leading to renal interstitial fibrosis and glomerulosclerosis.31 From a pathological perspective, this process can evolve from acute reversible injury to chronic renal structural remodeling and progressive functional decline, ultimately mediating the irreversible transformation of AKI into CKD. RIRI is mainly divided into two stages: primary injury during ischemia and secondary injury during reperfusion. The pathological mechanisms are interrelated and cascade amplified, forming a closed-loop injury network, which is the core pathological basis for the occurrence and progression of acute kidney injury to chronic kidney disease. The occurrence, severity, and recovery ability of RIRI exhibit significant gender dimorphism. Renal tubular epithelial cells, especially proximal tubular mitochondria, are abundant and oxygen consuming, and are extremely sensitive to ischemia and hypoxia, making them the main targets of RIRI. During the ischemic phase, renal hypoxia and ATP depletion induce cellular calcium homeostasis imbalance and mitochondrial dysfunction, initiating early oxidative stress and cellular damage, laying the foundation for subsequent injury occurrence. Hypoxia can stabilize HIF-1 α by inhibiting prolyl hydroxylase, induce oxidative stress disorder, and cause dysfunction of AMPK and Nrf2 signaling pathways, thereby activating inflammatory pathways such as NF-κB and MAPK, disrupting mitochondrial structure and function, triggering programmed cell death such as apoptosis, ferroptosis, and pyroptosis of renal tubular epithelial cells, while activating TGF-β and classical Wnt signaling pathways, mediating renal tubular epithelial mesenchymal transition, and initiating renal interstitial fibrosis process. During the reperfusion period, a sudden increase in oxygen supply triggers an oxygen explosion, with calcium overload as the early initiating factor. It is linked to NADPH oxidase mediated oxidative stress, forming a vicious cycle with mitochondrial dysfunction and continuously exacerbating DNA damage.32 Simultaneously overactivated endoplasmic reticulum stress, NF-κB, and NLRP3 inflammatory pathways induce a cascade of inflammatory factors, fully activating the immune system to participate in the injury process. Early RIRI can initiate innate immune response, promote large infiltration of neutrophils, macrophages and other inflammatory mediators, trigger acute inflammatory storm, further exacerbate oxidative stress and DNA damage, form a malignant loop of immune oxidative stress DNA damage, and amplify acute kidney injury.33,34 In the middle and late stages of injury, the adaptive immunity mediated by T and B lymphocytes is continuously activated, inducing persistent chronic inflammation and further promoting the progression of renal interstitial fibrosis,35,36 It is a key bridge connecting acute kidney injury and chronic kidney disease. The above-mentioned multiple damage signals can jointly activate various cell death modes such as apoptosis, programmed necrosis, and excessive autophagy of renal tubular epithelial cells, causing structural damage to renal tubules and acute decline in renal function. There are significant gender differences in the susceptibility of RIRI to injury. Women of childbearing age can exert protective effects through sex hormone regulation, with stronger tolerance, lighter damage, and better repair ability to RIRI, while men are more prone to severe RIRI. The protective effect of estrogen in postmenopausal women diminishes, and the susceptibility to injury is similar to that of men.13 In the later stage of injury, the persistent low-grade inflammation, chronic oxidative stress, and abnormal repair of renal tubules in different populations can further induce renal interstitial fibrosis and glomerulosclerosis, leading to irreversible structural remodeling and functional decline of RIRI mediated acute reversible kidney injury, ultimately leading to the prolonged progression of acute kidney injury into chronic kidney disease. Construction of RIRI Experimental Model A stable and standardized in vitro and in vivo modeling system is the core foundation for exploring the pathological mechanism of RIRI and verifying the intervention effect of nanomedicine. In recent years, high-level research has formed unified and standardized animal and cell modeling standards, greatly ensuring the reproducibility and scientificity of experimental results. Currently, mainstream research mainly focuses on rodent in vivo models combined with renal tubular epithelial cell in vitro models, while new humanized renal organ models are gradually being promoted and applied. Animal Model In animal model research, SPF grade male C57BL/6 mice and SD rats are the core experimental animals for constructing RIRI models. 8–12-week-old mice and 200–250 g rats have become universal experimental subjects due to their small individual differences, high uniformity of damage, and good experimental stability.37 The current mainstream modeling methods include three classic techniques that are suitable for different research directions. The bilateral renal ischemia-reperfusion model is constructed by clamping the bilateral renal pedicle to create an RIRI model. After 30–35 minutes of ischemia in mice and 45–60 minutes of ischemia in rats, renal dysfunction and severe tubular injury can quickly occur after reperfusion, which is suitable for studying the pathological mechanism and drug efficacy in the acute phase.38 The unilateral renal ischemia-reperfusion model only blocks unilateral renal blood flow, preserves the compensatory function of the contralateral kidney, and has a lower animal mortality rate. Combined with long-term reperfusion observation for 7–28 days, it can accurately simulate the transformation process from acute kidney injury to chronic kidney disease.39 A model of unilateral nephrectomy combined with contralateral renal ischemia was established to create severe injury through single kidney loading, with pathological features highly consistent with clinical IRI injury after kidney transplantation. The model had the best stability and ischemia time was controlled between 18 and 25 minutes.40 At the same time, in recent years, more attention has been paid to fine quality control in modeling. The rectal temperature of experimental animals is maintained at 37 ± 0.5 °C throughout the process, and postoperative warm physiological saline is supplemented at 0.2–0.3 mL/10g. The dorsal minimally invasive approach is gradually adopted to reduce the interference of surgical stress on experimental results.41 The successful construction of the model can be comprehensively judged by renal function indicators, renal pathology, and injury molecular markers, with Scr and BUN significantly elevated, tubular brush border detachment, interstitial inflammation infiltration, and high expression of KIM-1 and NGAL injury genes as the core judgment criteria.42 Cell Model In vitro cell models are an important means of analyzing the molecular mechanisms of RIRI cells and screening the activity of nanomedicines. At present, the scientific research field focuses on human HK-2 renal tubular epithelial cells and rat NRK-52E cells as the core experimental cells. The oxygen-glucose deprivation/reoxygenation (OGD/R) model is a standardized modeling protocol, which simulates renal ischemia by culturing in a 1% low oxygen, sugar-free environment for 6–12 hours, restores normal oxygen, and completes reoxygenation injury construction by culturing in complete medium for 2–24 hours. Cobalt chloride and sodium hydrosulfite are used to simulate hypoxia, which is low-cost but has poor damage stability. To address the complex pathological microenvironment within the adhesive body, current research often relies on 200–600μM H2O2 induced oxidative stress damage,43 Model of mitochondrial functional damage mediated by antimycin A,44 Alternatively, hypoxia combined with IL-1βcan be used to construct a composite injury system. In addition, human iPSC differentiated renal organoids, as a novel high-end in vitro model, can highly replicate the pathological structure of the human kidney. By simulating human RIRI injury through 1% O2 hypoxia treatment for 48 hours combined with reoxygenation for 2 hours, it effectively compensates for the shortcomings of traditional cell model species differences. The successful modeling of cell models is mainly evaluated based on reduced cell viability, increased LDH release, increased ROS accumulation, upregulation of apoptosis and specific injury markers.45 Nanomedicine: Basic Principles and Functional Roles in RIRI Therapy The treatment of RIRI currently faces diagnostic limitations and low treatment efficacy: existing biomarkers (such as serum creatinine and urea) have insufficient sensitivity to early kidney injury, often leading to delayed intervention measures until irreversible damage occurs. Although small molecule drugs have antioxidant and anti-inflammatory effects, they also suffer from low renal bioavailability and off target effects.46 Nanomedicine has shown unique advantages in RIRI treatment, and its basic principle lies in the use of nanocarriers. By utilizing the small size effect, barrier crossing ability, and controllable drug release characteristics of nanocarriers, it can break through the bottlenecks of traditional drug delivery efficiency, poor targeting, and insufficient bioavailability. Its functional role is mainly reflected in accurately targeting the site of renal injury, improving drug stability, prolonging circulation time in the body, and achieving efficient protection of RIRI by regulating key pathological processes such as oxidative stress, inflammatory response, and apoptosis of renal tubular epithelial cells.47 In terms of drug-controlled release, nanocarriers rely on their own structure and physicochemical properties to encapsulate and adsorb drugs, isolate enzymatic hydrolysis, acid-base and oxidative reactions in the body, protect drug stability and improve bioavailability. At the same time, it can achieve long-term sustained release through material degradation, pore diffusion, and other methods, smoothly control blood drug concentration, and prolong drug action time. By utilizing microenvironmental response mechanisms such as pH, reactive oxygen species, and enzymes, targeted and on-demand drug release can be achieved in lesions, combined with EPR passive targeting or ligand mediated active targeting to reduce drug exposure to normal tissues and minimize toxic side effects. It can also flexibly regulate the drug release rate to adapt to different treatment scenarios, co-load multiple drugs to achieve synergistic therapy, and improve the solubility of hydrophobic drugs, broaden the route of administration, effectively compensate for the shortcomings of traditional drugs such as short half-life, poor targeting, and significant toxic side effects. It has become an important carrier for controlled drug release and precision therapy.48–50 In terms of immune clearance, nanocarriers mainly avoid the body’s immune clearance mechanism by optimizing their physical and chemical properties and surface modification. Hydrophilic long chains, such as polyethylene glycol (PEG) and zwitterionic polymers are used for surface modification, forming a hydration protective layer on the outer layer of particles to reduce non-specific adsorption of plasma proteins and the regulatory effect mediated by regulatory factors, thereby avoiding recognition and phagocytosis by the reticuloendothelial system such as macrophages and monocytes. Simultaneously regulating particle size between 10–100nm, using near neutral surface charges, reducing electrostatic interactions between particles and immune cells, and activating the complement system. In addition, the use of biocompatible biodegradable materials and the reduction of surface hydrophobicity can further weaken immunogenicity and inflammatory reactions, prolong the in vivo blood circulation half-life of nanocarriers, and improve targeted delivery efficiency.51–53 Based on the advantages of the above-mentioned nanocarriers and the pathological mechanism of RIRI, various natural active monomers and small molecule drugs have gradually been combined with nano platforms to optimize the therapeutic effect of RIRI. For example, dexamethasone has been loaded into polyethylene glycol polylactic acid nanospheres for the treatment of mesangial proliferative glomerulonephritis, which has precise targeting and higher biocompatibility.54 Berberine (BBR) is an isoquinoline alkaloid extracted from traditional herbs with antioxidant properties, but its clinical prospects are limited by its poor gastrointestinal absorption and low bioavailability. So Xie et al combined berberine with nanoparticles to form berberine nanoparticles (BBR-NP), which protect the kidneys from I/R damage by inhibiting oxidative stress and mitochondrial stress. Compared with the BBR group, BBR-NP resulted in a greater decrease in serum urea nitrogen and creatinine levels. Compared with the corresponding low-dose group, higher doses of BBR or BBR-NP led to a sharp decrease in serum urea nitrogen and creatinine levels. Studies have found that the combination of berberine and nanoparticles is more effective than using them alone, proving that combining the drug with nanoparticles can improve the therapeutic effect on RIRI.55 NMDA receptor antagonists (5-phosphano-d-norveraline, DAP5) and resveratrol (Res) can improve renal I/R injury, but their poor water solubility and stability limit their application. Similarly, Xu et al combined DAP5 and Res with nanoparticles and found that they can regulate the AKT/NMDA/CaMK/DAPK and NF-κB signaling pathways to inhibit cell apoptosis and inflammatory response. It can effectively protect the kidneys from I/R damage. Studies have shown that nanoparticles can overcome the rapid clearance and low bioavailability of Res to increase its delivery, thereby improving the treatment of RIRI.56 Compared with conventional free drugs, nanomedicine achieves therapeutic advantages such as targeted enrichment, long-term retention, on-demand drug release, and multi-target synergy. The core differences between the two are shown in (Table 1). Table 1Comparison Between Conventional Drugs and Nanoscale Delivery Systems in RIRI TreatmentCharacteristicConventional DrugsNano Delivery SystemsInfluenceReferencesDelivery mechanismPassive diffusion as free moleculesPassive/active targeting of nanocarriersPrecise accumulation at injured sites[54]Targeting abilityLowHighSpecific recognition of injured tissues/cells[54]BiosafetyLowHighReduced immunogenicity and systemic toxicity[54]Drug release and circulationRapid release, short half-lifeSustained release, prolonged circulationSustained effective drug concentration[56]Particle sizeRelatively largeSmallEnhanced penetration and cellular uptake[46]StabilityPoorGoodReduced degradation and inactivation[56] Table 1Comparison Between Conventional Drugs and Nanoscale Delivery Systems in RIRI TreatmentCharacteristicConventional DrugsNano Delivery SystemsInfluenceReferencesDelivery mechanismPassive diffusion as free moleculesPassive/active targeting of nanocarriersPrecise accumulation at injured sites[54]Targeting abilityLowHighSpecific recognition of injured tissues/cells[54]BiosafetyLowHighReduced immunogenicity and systemic toxicity[54]Drug release and circulationRapid release, short half-lifeSustained release, prolonged circulationSustained effective drug concentration[56]Particle sizeRelatively largeSmallEnhanced penetration and cellular uptake[46]StabilityPoorGoodReduced degradation and inactivation[56] Comparison Between Conventional Drugs and Nanoscale Delivery Systems in RIRI Treatment In RIRI treatment, traditional formulations of free drugs commonly have three core drawbacks after systemic administration. One of them is serious off target effects: free drugs do not have tissue targeting properties, and only a small portion can accumulate in damaged renal tubular tissue. Most drugs will diffuse to normal organs such as the heart, liver, spleen, and lungs, resulting in insufficient drug concentration in the target area of the lesion and ultimately poor treatment effect. The second is significant systemic toxicity and side effects: In clinical practice, the effective concentration of drugs in the lesion is often increased by increasing the dosage, but high-dose drugs can easily cause adverse reactions such as liver and kidney damage, hemolysis, and immune stimulation, especially further damaging the already fragile kidney function after ischemia. At the same time, free small molecule drugs can quickly enter the liver through the portal vein and be non-specifically engulfed by Kupffer cells and sinusoidal endothelial cells in the liver. This not only causes problems such as fast liver metabolism, high clearance rate, and low bioavailability of drugs, but also induces significant liver toxicity. The third reason is poor pharmacokinetic performance: free drugs have a short half-life and are easily inactivated by enzymatic hydrolysis in the body, requiring frequent and high-dose administration, which further exacerbates the risk of off target drug delivery and systemic toxicity reactions.57,58 To address the above shortcomings, nanocarriers suitable for RIRI therapy need to meet multiple core performance requirements. Firstly, it is necessary to have specific renal targeting ability and microenvironment response characteristics: biomimetic-targeting structures such as surface-modified renal tubular targeting peptides, targeted antibodies, neutrophil/macrophage membranes, etc., as well as ROS, pH, MMP enzyme response mechanisms, can be carried out to achieve precise enrichment and controlled release of drugs in damaged renal tubules.59–61 Secondly, it is necessary to have excellent biocompatibility, bioavailability, and cycling performance: the carrier material needs to have characteristics such as degradability, no immunogenicity, no hemolysis, and no cytotoxicity, low toxicity and low liver accumulation, without increasing the burden on liver and kidney metabolism, while balancing high drug loading rate and high stability. By controlling the particle size between 20 nm and 100 nm, performing hydrophilic invisible modifications such as PEG, and regulating the carrier potential to be near neutral or weakly negative, the phagocytic effect of the reticuloendothelial system and liver retention can be reduced, effectively prolonging the half-life of drug blood circulation.62 Finally, it is necessary to have synergistic therapeutic effects of antioxidant, anti-inflammatory, and off target: the nanocarrier itself can clear excess ROS in the body, inhibit local inflammatory reactions, and form a synergistic effect with the loaded drug. At the same time, it effectively reduces the accumulation and distribution of drugs in non-target organs such as the liver and spleen, greatly improving the drug safety window.52 Application of Nanomedicine in Renal Ischemia-Reperfusion Injury At present, there are a wide variety of nanosystems applied in RIRI research, mainly including inorganic nanoparticles, polymer nanoparticles, nano-enzymes, cell membrane camouflage nanoparticles, extracellular vesicles, injectable hydrogels (Figure 2), which can achieve early diagnosis, acute treatment, long-term anti fibrosis full cycle intervention, and form an integrated diagnosis and treatment system. Figure 2Schematic illustration of nanoplatforms used for RIRI therapy. Major nanotherapeutic systems include inorganic nanoparticles, polymeric nanoparticles, nanozymes, extracellular vesicles, membrane–camouflaged nanoparticles, and injectable hydrogels.The diagram illustrates various nanotherapy systems for renal ischemia reperfusion injury. At the center is an image of a kidney labeled ′Nano therapy for renal ischemia reperfusion injury.′ Surrounding it are six sections, each depicting a different nanotherapeutic system. These include: Inorganic nps, Polymer nps, Nanoenzyme, Membrane disguised nps, Extracellular vesicle and Injectable hydrogel. Each section contains an illustration representing the respective system.Diagram of nanotherapy systems for renal ischemia reperfusion injury. Schematic illustration of nanoplatforms used for RIRI therapy. Major nanotherapeutic systems include inorganic nanoparticles, polymeric nanoparticles, nanozymes, extracellular vesicles, membrane–camouflaged nanoparticles, and injectable hydrogels. Auxiliary Diagnosis of Nanomedicine in Renal Ischemia-Reperfusion Injury Nanomaterials can be organically combined with multimodal imaging technologies such as magnetic resonance imaging, fluorescence imaging, mass spectrometry imaging, and ultrasound molecular imaging, as well as functional probes, to construct targeted microbubbles, nanodiagnostic agents, functional nanoparticles, AIE near-infrared small molecule probes, gold nanoclusters, and other multifunctional imaging reagents. They can accurately target the pathological microenvironment and specific targets of renal ischemia-reperfusion injury, and show great potential for early diagnosis, microcirculation evaluation, pathological state monitoring, and molecular mechanism analysis of renal ischemia-reperfusion injury. Traditional clinical practice relies on biochemical indicators such as serum creatinine and urea nitrogen, which have shortcomings such as delayed diagnosis, no obvious abnormalities in the early stage, and inability to capture the optimal intervention timing. Conventional pathological testing also has limitations such as invasiveness, limited sensitivity, and difficulty in early identification of unilateral minor injuries. The nano based imaging system can effectively overcome these limitations: Hu et al combined 19F magnetic resonance imaging (MRI) with perfluorocarbon nanoparticles (PFC NPs) and found that PFC NPs can sensitively detect renal vascular injury, tissue perfusion, and oxygenation status. They can quantitatively evaluate the degree of renal injury and repair process through signal changes. Experimental results have shown that in the cortical medullary junction area, after 24 hours of initial ischemia-reperfusion injury, the 19F signal of the damaged kidney decreases by 25%, which has high diagnostic ability and can be used as a new method for evaluating renal function and pathological status.63 The renal clearing AIE NIR-II small molecule nano probe can target the oxidative stress microenvironment of renal tubules, achieving non-invasive diagnosis at the minute level after reperfusion in the ultra early stage. It can also quantify the degree of injury through fluorescence signal layering, and is suitable for real-time monitoring of multifactorial renal ischemia-reperfusion injury. The construction of NIR-II fluorescence/mass spectrometry dual-mode imaging platform using gold nanoclusters not only significantly detects damage ahead of traditional blood and pathological tests, but also enables non-invasive in vivo localization, high-sensitivity identification of unilateral early damage, reduces false negatives, and in situ analysis of renal metabolic molecular characteristics. The probe has good biocompatibility, in vivo metabolic clearance, and is easy to prepare on a large scale, with outstanding clinical translational value. Nano-targeted microbubbles loaded with VCAM-1 targeting peptides can specifically identify inflammatory targets related to renal injury, and accurately evaluate changes in renal microcirculation perfusion and inflammatory response through ultrasound molecular imaging, providing a new approach for early non-invasive diagnosis of renal ischemia-reperfusion injury.64 Various targeted imaging reagents constructed by the combination of nanomaterials and multimodal imaging technology can accurately target renal ischemia-reperfusion injury lesions: perfluorocarbon nanoparticles can quantitatively evaluate renal tissue perfusion and injury degree, AIE near-infrared probes can achieve ultra early rapid diagnosis and quantification of injury, gold nanoparticle cluster dual-mode imaging has the advantages of early screening, in vivo localization, and metabolic analysis, and targeted nano microbubbles facilitate non-invasive evaluation of microcirculation and inflammatory status. Overall, the nano imaging system effectively breaks through the limitations of traditional detection and has good research value and potential clinical application significance in early diagnosis, dynamic monitoring, and mechanism research of this disease. Only some imaging methods have shortcomings such as high equipment requirements, weak tissue penetration, or complex detection processes. Treatment of Nanomedicine in Renal Ischemia-Reperfusion Injury Nanodrugs do not repair kidney damage through a single pathway, but rely on targeted drug delivery and precise regulation of the microenvironment to form a three-level intervention effect of blockade repair reversal at key pathological nodes such as RIRI oxidative stress, calcium overload, inflammatory activation, cell death, and fibrosis progression. Inorganic nanoparticles mainly inhibit oxidative stress, inflammation, cell apoptosis, and provide mitochondrial protection; Polymeric nanoparticles inhibit inflammatory infiltration, alleviate renal tubular epithelial apoptosis, and improve microcirculation through drug delivery and sustained release. Nanoenzymes may be particularly associated with ROS outbreaks, blocking inflammatory storms, and stabilizing mitochondrial structures. Cell membrane wrapped nanoparticles may be more suitable for targeting inflammatory cells and endothelial interactions. Extracellular vesicles and hydrogels may play a stronger role in repair, immune regulation and AKI to CKD transition. Different nanocarriers have significant differences in intervention mechanisms, therapeutic advantages, application shortcomings, and clinical adaptation scenarios based on their own physicochemical properties (Table 2). Table 2Comprehensive Comparison of Six Categories of Nanocarriers for RIRIType of NanocarrierAdvantagesLimitationsReferencesInorganic nanoparticlesHigh stability, large surface area, tunable composition, multifunctionality, specific biological responsesPotential organ accumulation and toxicity[65,66]Polymeric nanoparticlesSmall size, controllable drug release, improved stability and bioavailability, high biocompatibilityChallenges in large‑scale production, encapsulation efficiency, and stability[67,68]NanozymesLow cost, high stability, controllable catalytic activity, excellent reusabilityUnclear catalytic mechanisms, insufficient specificity[69,70]Cell membrane‑camouflaged nanoparticlesImmune evasion, inflammatory targeting, good biocompatibilityComplex membrane extraction process[71,72]Extracellular vesiclesCell‑free strategy, good stability, multi‑mechanism therapeutic effectsUnclear uptake mechanisms, lack of standardized production[73,74]Injectable hydrogelsHigh biocompatibility, biodegradability, local/sustained releasePossible carrier–drug antagonism, local injection risks[75,76] Table 2Comprehensive Comparison of Six Categories of Nanocarriers for RIRIType of NanocarrierAdvantagesLimitationsReferencesInorganic nanoparticlesHigh stability, large surface area, tunable composition, multifunctionality, specific biological responsesPotential organ accumulation and toxicity[65,66]Polymeric nanoparticlesSmall size, controllable drug release, improved stability and bioavailability, high biocompatibilityChallenges in large‑scale production, encapsulation efficiency, and stability[67,68]NanozymesLow cost, high stability, controllable catalytic activity, excellent reusabilityUnclear catalytic mechanisms, insufficient specificity[69,70]Cell membrane‑camouflaged nanoparticlesImmune evasion, inflammatory targeting, good biocompatibilityComplex membrane extraction process[71,72]Extracellular vesiclesCell‑free strategy, good stability, multi‑mechanism therapeutic effectsUnclear uptake mechanisms, lack of standardized production[73,74]Injectable hydrogelsHigh biocompatibility, biodegradability, local/sustained releasePossible carrier–drug antagonism, local injection risks[75,76] Comprehensive Comparison of Six Categories of Nanocarriers for RIRI Inorganic Nanoparticles Inorganic nanoparticles are a type of nanoparticle with various morphologies and particle sizes ranging from 1–100 nanometers that can be synthesized through physical or chemical methods.77 Made of metals, metal oxides, alloys, carbon, and other types of inorganic materials.78 Inorganic nanoparticles are becoming a promising drug delivery carrier due to their high stability, large specific surface area, adjustable composition, rich physical and chemical properties, multifunctionality, and specific biological responsiveness.65 Taking the PEG modified gold nanoparticles (PEG AuNPs) constructed by Saleh et al as an example, PEG AuNPs can activate the AMPK/PI3K/AKT signaling axis after tail vein injection into mice The activated AMPK positively regulates the PI3K/AKT signaling molecule and promotes its phosphorylation, thereby initiating the downstream Nrf2 signaling pathway. Under normal conditions, Nrf2 binds to Keap1 and is degraded, while phosphorylated AKT can promote the dissociation of Nrf2 from Keap1, allowing free Nrf2 to enter the nucleus and bind to antioxidant response elements (ARE), initiating the transcription and protein expression of downstream antioxidant enzyme genes such as HO1. Highly expressed HO-1 can clear excessive reactive oxygen species, inhibit lipid peroxidation, reduce mitochondrial oxidative damage, and alleviate oxidative stress-induced release of inflammatory factors and cell apoptosis. It improves renal ischemia-reperfusion injury from multiple targets of oxidative stress, inflammatory response, and energy metabolism, and has good biocompatibility at experimental doses without significant toxic side effects.79 At the same time, PEG relies on steric hindrance and hydration layer effect to enhance the colloidal stability of nanoparticles, achieve immune escape in vivo, and reduce non-specific excessive endocytosis of renal tubular epithelial cells, thereby reducing the risk of cell damage and demonstrating considerable clinical translational value. However, research by Ding et al suggests that insufficiently modified gold nanoparticles are prone to excessive uptake by renal tubular epithelial cells in a hypoxic pathological microenvironment, abnormally activating autophagy and apoptosis pathways, exacerbating renal cell damage, and highlighting their inherent toxicity hazards.80 In summary, the efficacy and toxicity of gold nanoparticles highly depend on surface modification strategies, particle size, and lesion microenvironment. Gold nanoparticles that are unmodified or insufficiently modified are prone to cell toxicity, while reasonable surface functionalization modifications such as PEG can effectively avoid toxic side effects and amplify therapeutic effects. In the future, further optimization of structural design is needed to balance their therapeutic effects and potential toxicity, and promote the development of safe and effective kidney targeted nanomedicines. In addition, Xu et al prepared multifunctional nanoparticles using a soft template method combined with chelation reaction, with Fe3O4 and strontium ions as functional substrates, mesoporous polydopamine as the shell, and loaded with TNK-tPA FeM@Sr-TNK NPs. This nano material has good biocompatibility, relying on the inherent superparamagnetism, high specific surface area, and easy separation of Fe3O4. It can not only accurately enrich drugs in thrombotic lesions through magnetic targeting, but also significantly prolong the half-life of thrombolytic drugs to 3.04 times that of free TNK-tPA, effectively exerting thrombolytic effects. The results of in vivo and in vitro experiments confirm that, FeM@Sr-TNK NPs can effectively eliminate excessive reactive oxygen species and nitrogen species in the body, significantly downregulate the expression of Bax and Caspase-3 pro apoptotic proteins, inhibit apoptosis of renal tubular epithelial cells, and regulate angiogenesis, reduce collagen fiber deposition in renal tissue, alleviate renal fibrosis, thereby significantly reducing tissue lesions caused by renal ischemia-reperfusion injury and improving renal function.81 In addition, the nano platform integrates magnetic response, photoacoustic imaging, and magnetic hyperthermia technology, successfully achieving an integrated intervention of “diagnosis treatment protection” from thrombus diagnosis and treatment to renal IRI protection, providing a new strategy for the comprehensive treatment of thrombus related complications. Fe-O-based nanoparticles play a dual role in thrombolysis and renal protection due to their superparamagnetism, enzyme like activity, and modifiability. On the one hand, they can be targeted and enriched at the thrombus site under the mediation of an external magnetic field, achieving precise thrombolysis by loading thrombolytic drugs, magnetocaloric effect, and inhibiting platelet aggregation, improving renal microcirculation, and dissolving renal microvascular microthrombi. On the other hand, by clearing reactive oxygen species, inhibiting inflammatory pathways, reducing apoptosis and pyroptosis of renal tubular epithelial cells, regulating iron homeostasis, alleviating renal oxidative stress and ischemia-reperfusion injury, the two can work together to unblock renal blood flow and block the vicious cycle of ischemic injury, achieving integrated treatment of thrombolysis and renal protection.81,82 At present, iron oxide nanomaterials have shown great potential for application in fields such as magnetic resonance imaging, targeted hyperthermia, and drug delivery. However, there are still shortcomings, and further in-depth toxicology research is needed to clarify their in vivo safety characteristics, develop economical and efficient large-scale preparation processes, and further optimize the comprehensive performance and biocompatibility of nanoparticles through surface modification technology to promote their clinical translational applications.83 Zhou et al prepared cerium oxide nanoparticles using thermal decomposition method and pre treated them before ischemia-reperfusion. It was found that cerium oxide nanoparticles not only have good antioxidant and anti-inflammatory activities, but also reduce macrophage infiltration and M1 phenotype polarization, reduce the production of pro-inflammatory cytokines and chemokines, thereby alleviating RIRI induced inflammatory responses. It can last for more than 21 days in damaged kidneys, and its persistence and antioxidant capacity in damaged kidneys enable it to effectively prevent the progression of RIRI induced renal fibrosis.84 Cerium oxide (CeO2) nanoparticles rely on the reversible valence state cycle of Ce3+/Ce4+ on their surface to exert multiple nanoenzyme activities such as SOD and CAT, efficiently and continuously clearing reactive oxygen species to alleviate oxidative stress damage. It can inhibit the activation of inflammatory signaling pathways by clearing ROS, alleviate apoptosis and pyroptosis of renal tubular epithelial cells, and does not have Fenton reaction toxicity. It will not generate hydroxyl radicals due to the release of metal ions, and has higher biological safety in oxidative stress injury models.85,86 Similarly, Awadalla et al combined ferulic acid and zinc oxide nanoparticles (ZnO NPs) in rat RIRI and found that their combined application had a more significant renal protective effect than using them alone. This protective effect may be attributed to stronger antioxidant capacity, higher expression levels of antioxidant genes, and more significant anti-inflammatory and anti apoptotic effects.87 However, this experiment did not use experimental techniques to detect the distribution and form of nanoparticles in kidney tissue, and could not directly confirm the site and mode of action of ZnO NPs in the kidney. And the study only observed the short-term (up to 7 days) renal protective effect, lacking evaluation of long-term prognosis and potential adverse reactions. Mesoporous silica nanoparticles (MSNs) have a pore size distribution of 2–50nm. The characteristics of MSN include a wide range of adjustable specific surface area, pore size, particle size, and morphology, diverse surface functionalization properties, and excellent biocompatibility.88 Deng et al prepared a mesoporous nanoparticle (TP MNPs) loaded with Triptolide (TP) with kidney targeting ability using the nanoprecipitation method. They conducted experiments on RIRI mice and found that TP MNPs could significantly reduce serum creatinine and urea nitrogen levels, inhibit apoptosis of proximal tubular epithelial cells, and alleviate pathological damage to kidney tissue. Moreover, TP MNPs can effectively protect the kidneys from IRI damage at low doses (0.01 mg/kg), while free TP at the same dose is ineffective, indicating the superiority of mesoporous nanoparticles as a drug carrier. Secondly, the concentration of TP in the kidneys is more than 50 times that of other tissues, and its retention time is up to 7 days, demonstrating that TP MNPs exhibit excellent renal targeting ability and drug persistence in vivo.89 In addition, Varshosaz et al combined mesoporous silica (MS) with alumina nanoparticles to study the drug delivery effect of pioglitazone (PIO) on type 1 diabetes nephropathy in rats. The results showed that the parameters of PIO and insulin groups were significantly reduced compared with the control group. Compared with the PIO group, the levels of urea nitrogen, triglycerides, low-density lipoprotein, and blood glucose in the PIO-MS group were further significantly reduced. It is proved that the mesoporous alumina and silica nanoparticles loaded with pioglitazone can improve the solubility and stability of pioglitazones, prevent the development of diabetes nephropathy, improve hyperlipidemia and significant renal function parameters. The mechanism is that peroxisome proliferator activated receptor gamma agonist improves diabetes nephropathy in type 1 diabetes rats through anti-inflammatory effect.90 However, this view needs more large-scale research to determine its impact on diabetes nephropathy. In summary, MSNs can enhance the renal targeted therapeutic effect of drugs through multiple advantages. On the one hand, MSNs can achieve passive renal targeted enrichment through nanoscale regulation, and preferentially accumulate in renal tissue after glomerular filtration, significantly increasing the local concentration of drugs such as Triptolide in the kidneys; On the other hand, MSNs as porous carriers can improve the solubility and stability of hydrophobic drugs, avoid rapid systemic clearance of free drugs, and prolong the retention time of drugs in the kidneys. At the same time, the carrier protects the drug by reducing systemic toxic side effects, achieving significant renal protection at low doses, and ultimately improving the efficacy of drug targeted therapy through efficient renal enrichment and slow drug release. Wang et al developed a nano carrier based on silica cross-linked micelles (SCLMs) of different sizes for targeted delivery of drugs to damaged kidneys. Loading atorvastatin into 13 nanometer SCLMs to prepare atorvastatin loaded silica crosslinked micelles (Ator@SCLMs) Conduct research on human renal tubular epithelial cells and mouse ischemia-reperfusion injury models. Research has found that 13 nanometer SCLMs can quickly penetrate the glomerular barrier membrane, target damaged renal tubular cells, and accumulate at the site of injury. And Ator@SCLMs it can significantly improve renal function indicators, increase the activity of antioxidant enzymes such as super oxide dismutase (SOD), reduce oxidative stress markers such as malondialdehyde (MDA) levels, and also reduce the expression of cell apoptosis and renal fibrosis markers (such as α - smooth muscle actin and collagen I), delaying the progression of AKI to chronic kidney disease.91 Zuo et al’s experiment used human clinical samples and RIRI mice to demonstrate that selenium nanoparticles (SeNPs) upregulate lysosome associated membrane protein 1 and inhibit ferritin autophagy mediated by nuclear receptor co activator 4, reducing the accumulation of Fe2+ in lysosomes and alleviating iron death in TECs. In the I/R-AKI mouse model, SeNPs reduced serum creatinine and urea nitrogen levels, decreased inflammatory cell infiltration, and improved renal tubular injury. The combination of selenium and nanoparticles has high targeting efficiency, multifunctionality, and biocompatibility.92 However, this experiment cannot rule out the possibility that the decrease in ferritin levels may be due to a reduction in ferritin synthesis, and the exact mechanism of selenium nanoparticle action needs further investigation. In addition to inhibiting ferritin autophagy and reducing lysosomal Fe2+ accumulation through the XBP1/NCOA4 pathway, selenium nanoparticles can also enhance antioxidant capacity by regulating the GPx1/NLRP3/Caspase 1 pathway, upregulating glutathione peroxidase 1 (GPx1), inhibiting NLRP3 inflammasome and downstream Caspase 1 activation, reducing pro-inflammatory cytokine release, and alleviating renal oxidative stress and inflammatory response. Simultaneously, it can improve renal function indicators, reduce renal tubular injury and cell apoptosis, and exert renal protective effects through the dual pathways of antioxidant and anti-inflammatory.93 Zheng et al synthesized porous selenium @ silica nanospheres (Se@SiO2) Using human renal proximal tubular cells and mouse models, research has shown that Se@SiO2 By directly inhibiting the inflammatory signaling pathway or indirectly exerting antioxidant effects, oxidative stress and inflammatory response can be reduced, I/R-induced AKI can be alleviated, and renal prognosis can be improved. And the ones used in the experiment Se@SiO2. The dosage of nanospheres did not cause significant liver or kidney toxicity and had good biocompatibility.94 This study combines inorganic nanomaterials (selenium, silica) with nanosphere structures to construct a multifunctional nanomedicine with dual antioxidant and anti-inflammatory effects, breaking through the limitations of single efficacy nanomedicines. Simultaneously paying attention to the long-term prognosis of nanomedicine on kidney injury (fibrosis, tubular atrophy) fills the gap of previous studies focusing on short-term protective effects, providing a new nanomedicine strategy for long-term intervention of AKI, and its good biocompatibility provides an important prerequisite for clinical translation. However, this study only used human renal proximal tubular cells and mouse models, lacking human clinical trial data, making it difficult to directly translate into clinical applications. The preparation process of porous structures is complex, and large-scale production is difficult. At the same time, the metabolic pathways, clearance rates, and long-term accumulation risks of Se@SiO2 nanospheres in the body are not clear, as well as the differences in therapeutic effects on different degrees of AKI, have not been explored, which limits their clinical applicability. The commonly used inorganic nanoparticles mentioned above have their own advantages: gold nanoparticles (such as PEG AuNPs) have good biocompatibility, modifiability, and optical properties, are easy to achieve surface functionalization modification, can regulate pathological processes such as oxidative stress and inflammatory response in multiple stages, and have low toxicity at experimental doses, making them suitable for multi-target synergistic therapy. At the same time, their unique surface plasmon resonance characteristics are also applicable to the field of medical imaging. Iron oxide nanoparticles (such as Fe3O4 nanoparticles) have the characteristics of superparamagnetism, high specific surface area, and easy separation, which can achieve the integration of magnetic targeted drug delivery, magnetic resonance imaging, and magnetic hyperthermia. They can significantly prolong drug half-life, accurately target lesion sites, and demonstrate outstanding advantages in diagnosis and treatment integration in diseases such as thrombosis related kidney injury. Cerium oxide nanoparticles have excellent antioxidant activity, can simulate the function of superoxide dismutase to remove reactive oxygen species, and can remain in the damaged kidney for a long time (more than 21 days). They have significant effects on inhibiting renal fibrosis and reducing inflammatory reactions, making them suitable for long-term intervention in chronic kidney injury. Mesoporous silica nanoparticles (MSNs) have adjustable specific surface area, pore size, and morphology, diverse surface functionalization, strong drug loading capacity, and can significantly improve drug solubility and stability. They can also achieve kidney targeted delivery, reduce the toxicity of free drugs, and have significant advantages in the field of insoluble drug delivery. Selenium nanoparticles can alleviate cell iron death by regulating ferritin autophagy, and combined with research on human clinical samples, make them more clinically relevant and biocompatible, providing a new target for the treatment of renal ischemia-reperfusion injury. Therefore, the use of inorganic nanoparticles needs to be selected based on specific application scenarios (Table 3). Table 3Applications, Mechanisms, Advantages, and Limitations of Inorganic Nanoparticles in RIRITypeTherapeutic AgentMechanismAdvantageLimitationReferencesGold nanoparticlesPolyethylene glycolAMPK/PI3K/AKT pathway, regulating oxidative stress, inflammationComprehensive therapeutic potential, good biocompatibility, stability, and modifiabilityExcessive endocytosis increases autophagy and apoptosis in hypoxic HK-2 cells[79,80]Iron oxide nanoparticlesTenecteplaseScavenging reactive oxygen and nitrogen species, regulating cell apoptosis, angiogenesis and fibrosisSuperparamagnetism, high specific surface area, easy separation, precise delivery, integrated diagnosis and treatmentUnverified long-term safety and high production cost[81]Zinc oxide nanoparticlesFerulic acidEnhancing antioxidant and anti-inflammatory effectsStronger antioxidant capacity and anti-inflammatory effectUnconfirmed in vivo action site and mode[87]Mesoporous silica nanoparticlesTriptolideInhibiting inflammation and cell apoptosisAdjustable specific surface area, pore size and morphology, diverse surface functionalization, excellent biocompatibilityLack of large-scale efficacy verification[89,90]Selenium nanoparticlesSeleniumRegulating XBP1/NCOA4 pathway and ferroptosisHigh targeting efficiency, multifunctionality, favorable biocompatibilityUnclear exact mechanism; decreased ferritin may be related to reduced synthesis[92] Table 3Applications, Mechanisms, Advantages, and Limitations of Inorganic Nanoparticles in RIRITypeTherapeutic AgentMechanismAdvantageLimitationReferencesGold nanoparticlesPolyethylene glycolAMPK/PI3K/AKT pathway, regulating oxidative stress, inflammationComprehensive therapeutic potential, good biocompatibility, stability, and modifiabilityExcessive endocytosis increases autophagy and apoptosis in hypoxic HK-2 cells[79,80]Iron oxide nanoparticlesTenecteplaseScavenging reactive oxygen and nitrogen species, regulating cell apoptosis, angiogenesis and fibrosisSuperparamagnetism, high specific surface area, easy separation, precise delivery, integrated diagnosis and treatmentUnverified long-term safety and high production cost[81]Zinc oxide nanoparticlesFerulic acidEnhancing antioxidant and anti-inflammatory effectsStronger antioxidant capacity and anti-inflammatory effectUnconfirmed in vivo action site and mode[87]Mesoporous silica nanoparticlesTriptolideInhibiting inflammation and cell apoptosisAdjustable specific surface area, pore size and morphology, diverse surface functionalization, excellent biocompatibilityLack of large-scale efficacy verification[89,90]Selenium nanoparticlesSeleniumRegulating XBP1/NCOA4 pathway and ferroptosisHigh targeting efficiency, multifunctionality, favorable biocompatibilityUnclear exact mechanism; decreased ferritin may be related to reduced synthesis[92] Applications, Mechanisms, Advantages, and Limitations of Inorganic Nanoparticles in RIRI The adverse reaction of inorganic nanoparticles is their high accumulation in organs. For example, Jarrar et al’s experiments have shown that liver cells and renal tubular cells are the main targets of nanoparticle toxicity aggregation, ultimately leading to mitochondrial damage and cell damage.66 But existing research is already using chemical methods to modify the surface of inorganic nanoparticles to make them safer and less toxic. However, before the application of inorganic nanomaterials, various possibilities need to be verified, such as targeting, toxicity, and application dosage.95 In addition, the main toxicity of inorganic nanoparticles includes inducing excessive production of reactive oxygen species, causing oxidative stress, degrading and releasing free metal ions leading to ion accumulation, disrupting lysosomal homeostasis and autophagy balance, targeting accumulation in the kidney causing tubular damage, inducing mitochondrial dysfunction and activating inflammatory pathways such as NLRP3, thereby exacerbating cell iron death and inflammatory damage. Its toxicity is also closely related to particle size, surface charge, and modification mode, for example, the smaller the particle size, the stronger the toxicity. Positively charged nanoparticles are more likely to damage the cell membrane. Untreated nanoparticles are prone to aggregation, exacerbating tissue deposition and toxicity.92,96 Polymer Nanoparticles Polymer nanoparticles (NPs) have gained widespread attention in recent years due to their unique properties due to their small size (1–1000 nm). They have many advantages as drug carriers, such as achieving controlled drug release, protecting drugs from environmental influences, improving drug bioavailability and therapeutic index, etc. Polymer nanoparticles include nanocapsules and nanospheres, which differ in morphology and structure. These types of nanoparticles have shown great potential in targeted drug delivery and can be used for the treatment of various diseases.67 For example, polymer nanoparticles composed of polylactic acid (PlA), polyglycolic acid (PGA), and polylactic co glycolic acid (PLGA) are often used to carry therapeutic drugs, DNA, and proteins.97 PLA has strong hydrophobicity and slow degradation, making it suitable for long-term delivery of hydrophobic drugs. PGA has high hydrophilicity and rapid degradation, making it more suitable for short-term release of hydrophilic drugs but with poor stability. PLGA, as a copolymer of lactic acid and glycolic acid, combines the advantages of both. It can regulate the hydrophilicity, hydrophobicity, and degradation rate through monomer ratios, and has a wide drug loading range, excellent biocompatibility, and nanoformability. It is the most widely used polymer nanocarrier in drug delivery systems.98–100 In addition, Xu et al prepared curcumin loaded nanoparticles (Cur NPs) using distearoyl-sn-glycerin-3-phosphoyl-ethanolamine-glycol (DSPE-PEG) as a carrier, and investigated the therapeutic effect of Cur NPs on RIRI using human renal cortical proximal tubular epithelial cells. Research has shown that Cur NPs can significantly increase the survival rate of HK-2 cells exposed to IRI, reduce ROS levels, decrease MDA content, and increase SOD levels. Cur NPs exhibit significant protective effects against IRI induced kidney injury by reducing the expression of Caspase-3 and Bax proteins, increasing the expression of Bcl-2 protein, and exerting antioxidant and anti apoptotic effects. Polymer nanoparticles improve the water solubility of hydrophobic curcumin by encapsulating it, achieving slow drug release and prolonging circulation time, protecting the drug from degradation, promoting renal tubular epithelial cell uptake and renal enrichment, significantly enhancing the solubility, stability, and effective exposure of curcumin to target tissues, thereby increasing its bioavailability and enhancing its antioxidant and anti apoptotic protective effects against renal ischemia-reperfusion injury.101 Similarly, Yan et al prepared a self-assembled polyethylene glycol conjugated bilirubin 3 α nanoparticle BX-001N by flow chemistry method and injected fluorescently labeled BX-001N into mice. It was found that BX-001N was mainly distributed in the kidneys and spleen after IRI, while in the sham surgery group, it was mainly distributed in the liver and intestines. BX-001N can significantly inhibit ROS generation in neutrophils and macrophages, reduce the secretion of pro-inflammatory cytokines, and inhibit the elastase activity released from neutrophil extracellular traps. BX-001N, as a synthetic bilirubin based nanomedicine, not only has a significant protective effect on renal IRI in the acute phase, but also promotes renal recovery in the subacute phase and inhibits renal fibrosis in the chronic phase.102 Liu et al synthesized mitochondrial targeted triphenylphosphine coenzyme Q10 nanoparticles (T-NPCoQ10) using the ABC mitoarm polymer method, and established I/R injury models in human renal epithelial cell line HK-2 and male mice. After oxygen glucose deprivation/reperfusion therapy, it was found that 6.1% of cells in the T-NPCoQ10 group underwent apoptosis, 14.9% of cells in the CoQ10 alone group underwent apoptosis, and 25.7% of cells in the non mitochondrial targeted triphenylphosphine CoQ10 nanoparticle group underwent apoptosis, demonstrating that the T-NPCoQ10 group can significantly inhibit cell apoptosis. In the T-NPCoQ10 group, blood urea nitrogen and plasma creatinine concentrations were significantly reduced, and renal tubular injury was significantly improved. The research results showed that T-NPCoQ10 significantly alleviated oxidative damage in cells and animal models, reduced mitochondrial DNA damage, inhibited inflammation and apoptosis reactions, and improved renal function. Moreover, after treating mice with T-NPCoQ1 (50mg/kg) for 3 days, there was no difference in multiple liver and kidney indicators, indicating that the CoQ10 nanoparticles targeting mitochondria were well assembled and had no cytotoxicity or side effects.103 In addition, Zhang et al also used TPP modification to construct a mitochondrial targeted artemisinin nanoliposome delivery system (Artesunate Nanoliposome TPP, ART NL TPP). The study confirmed that artemisinin nanoliposomes modified with TPP can break through the limitations of conventional drug delivery, accurately enrich in the mitochondrial target sites of kidney damaged cells, and efficiently reverse mitochondrial dysfunction. This drug delivery system can inhibit the accumulation of reactive oxygen species upstream of pathology, alleviate oxidative stress damage, and effectively block the release of inflammatory factors and activation of inflammatory pathways, thus bidirectionally blocking the core pathological chain of cisplatin induced renal injury.104 In addition, Lin et al constructed a manganese oxide nanoenzyme with dual modifications of hyaluronic acid (HA) CD44 targeting and SS31 mitochondrial targeting (HMN@HA-SS31) Drug delivery system for targeted therapy of RIRI. In vitro experiments have shown that HMN@HA-SS31 It can reduce mtROS, restore membrane potential and network integrity, and significantly reduce cell apoptosis. In the mouse I/R-AKI model, HMN@HA-SS31 Passing through the damaged filtering barrier, accumulating in the damaged PTEC, reducing renal ROS, improving renal function and histopathology, inhibiting the cGAS STING pathway, limiting fibrosis under a multi dose regimen, and increasing the 21 day survival rate to 80% without detectable toxicity. These findings suggest that mitochondrial targeting can catalyze locally within the mitochondrial microstructural domain, thereby disrupting the mtROS inflammatory cycle in I/R-AKI.105 Mitochondrial dysfunction is the core hub of RIRI development. A nano drug delivery system based on mitochondrial targeting groups such as TPP and SS31 can accurately target the mitochondria of kidney damaged cells, intervene in the upstream core pathological mechanisms of RIRI, and effectively solve the problems of poor targeting, weak therapeutic efficacy, and obvious side effects of traditional drugs. Both single mitochondrial targeted drug delivery systems and cell targeted combined with mitochondrial targeted dual precision delivery systems can effectively treat various types of acute kidney injury such as ischemia-reperfusion and drug-induced injuries by repairing mitochondrial function, inhibiting oxidative inflammatory cascade reactions, and reducing cell apoptosis, with reliable safety. This type of mitochondrial targeted nanotherapy strategy provides a new research direction and technical support for the precise, efficient, and safe treatment of RIRI. Polymer nanoparticles are mainly enriched through renal targeting. On the one hand, they can directly clear excess reactive oxygen species and reduce lipid peroxidation in RIRI. On the other hand, they activate the Nrf2/ARE pathway to enhance the endogenous antioxidant capacity of the body, such as SOD and HO1. At the same time, they protect mitochondrial structure and function to inhibit the generation of ROS, thereby blocking oxidative stress-induced apoptosis, pyroptosis, and ferroptosis, improving renal microcirculation disorders, breaking the cascade of oxidative inflammation, and ultimately alleviating oxidative stress damage in RIRI.106–108 In addition, polymer nanoparticles, with their excellent kidney targeted enrichment properties, can precisely act on the site of renal ischemia-reperfusion injury to achieve local and efficient anti-inflammatory effects. By loading anti-inflammatory active substances or self functional groups, drug release can be achieved. At the same time, they can simultaneously inhibit the activation of NF-κB and NLRP3 inflammasomes, reduce the release of pro-inflammatory factors, block oxidative inflammatory cascade reactions, protect the renal vascular endothelial barrier, and inhibit inflammatory cell infiltration. Combined with its excellent biocompatibility and modifiability, it can achieve multi-target synergistic intervention, while reducing systemic toxicity and side effects, and exerting long-term and precise anti-inflammatory advantages.106,109 In summary, polymer nanoparticles can efficiently load small molecule drugs, proteins, and nucleic acids, improve the water solubility of poorly soluble drugs, achieve slow drug release in vivo, and enhance drug utilization efficiency. After functional modification, it can accurately target damaged kidney tissue and even mitochondria, selectively enrich lesions, effectively downregulate oxidative stress levels, inhibit inflammatory reactions and apoptosis of renal tubular epithelial cells. It can not only alleviate acute kidney damage, but also promote tissue repair and delay fibrosis process. This type of material has high biological safety, few adverse reactions, and can reduce the overall dosage of drugs. It is suitable for various administration methods and transplant related kidney injury research. Among them, PLGA can be used for transdermal delivery of nonsteroidal anti-inflammatory drugs and has FDA approved safety. However, there are still some practical problems in batch preparation, encapsulation efficiency, and formulation stability.68 Its large-scale production mainly faces the following challenges: uneven material mixing and unstable shear force after process scaling, which can easily cause uneven particle size and particle agglomeration. Small fluctuations in production parameters can easily amplify, leading to significant differences in performance such as particle size and encapsulation efficiency between batches. Purification methods such as centrifugation and ultrafiltration have low amplification efficiency and are difficult to remove solvent residues. High concentration systems are prone to aggregation, and sterilization can easily damage the particle structure. Lack of online quality control methods makes impurity control difficult. At the same time, there are problems such as high raw material costs, high environmental pressure on solvents, and long compliance verification cycles for medical products.110,111 Nanoenzymes Nanozyme is a type of nanomaterial with enzyme like catalytic activity, which is an artificial simulated enzyme that combines the physicochemical properties of nanomaterials with enzyme catalytic function. Compared with natural enzymes, natural enzymes are essentially proteins or RNA, with flexible structures, high substrate specificity but poor stability, easy deactivation, high preparation costs, and strict storage conditions. Nanoenzymes are mostly inorganic nanomaterials with stable structures, acid and alkali resistance, high-temperature resistance, easy large-scale preparation, room temperature storage, and easy surface modification to achieve multifunctional integration. However, substrate specificity is usually weaker than natural enzymes.69,112 However, traditional nanoenzymes suffer from issues such as non specificity, toxicity, and limited catalytic efficiency. In addition, nanoenzymes that only clear free radicals through exogenous pathways often have poor efficacy. Therefore, developing nanoenzymes with activated catalytic activity and adopting a multi-pathway synergistic enhancement strategy is of great significance for the treatment of renal diseases related to ROS/RNS. Jiang et al were the first to propose the concept of prefabricated nanoenzymes, which can be used for targeted treatment of ischemia-reperfusion injury in transplanted kidneys. A super-small platinum-based nanoenzyme (Pt5.65S) was successfully synthesized by reacting Pt cluster nanoenzyme (Ptzyme) with sodium sulfide (Na2S) using physical adsorption and ligand interaction methods. The Pt5.65S pre-fabricated nanoenzyme activates the Nrf2 signaling pathway, upregulates the expression of antioxidant gene GPX4, inhibits the NF-κB signaling pathway and the production of inflammatory factors, and exerts renal protection. In vitro experiments showed that Pt5.65S pre-fabricated nanoenzyme significantly improved cell tolerance to H2O2 induced oxidative stress, reduced intracellular ROS levels, decreased the production of lipid peroxidation product MDA, and increased SOD activity. In vivo experiments, Pt5.65S pre-fabricated nanoenzyme significantly reduced serum creatinine and urea nitrogen levels in AKI mice induced by IRI and cisplatin, alleviated renal pathological damage, and exhibited good distribution and clearance characteristics in the kidneys. This study provides important theoretical basis and experimental support for the development of novel nanoenzyme therapy for oxidative stress-related diseases.113 In summary, platinum-based nanoenzymes have multiple advantages in activating the Nrf2 signaling pathway. Firstly, they possess dual antioxidant enzyme activities similar to SOD and CAT, effectively clearing ROS and alleviating oxidative stress from the source to stabilize Nrf2 activation. Second, they have stable physical and chemical properties, are resistant to acid and alkali, and can sustainably and long-term regulate the dissociation of Keap1 Nrf2, avoiding the defects of natural enzyme inactivation and short-lived effects. Thirdly, the size and surface can be precisely controlled, with targeted enrichment at the site of injury. Low doses can effectively activate Nrf2 with low toxicity and side effects. Fourthly, it is easy to carry out surface modification, which can achieve targeted delivery and coordinated regulation of multiple pathways. It can stably upregulate downstream proteins such as HO1 and NQO1 and has a long-lasting and efficient antioxidant protection effect.114,115 Deng et al extracted macrophage membrane (MM) through low-permeability treatment and differential centrifugation, prepared platinum nanoparticles (PtNPs) using citric acid reduction method, and connected them with ROS degradable thioketone to form nanoclusters (PtNCs). PtNCs were mixed with MM and sonicated to construct biomimetic ROS responsive platinum nanoenzyme clusters MM PtNCs on macrophage membrane. The experiment used human renal tubular epithelial cells to establish a unilateral RIRI model in mice. MM PtNCs were injected through the tail vein. MM PtNCs were effective in clearing ROS, neutralizing inflammatory cytokines, reducing kidney damage, and promoting kidney repair in both in vitro and in vivo experiments. At high doses, they did not show acute toxicity and have the potential to become a new clinical treatment method for AKI.116 In addition, Xia et al synthesized manganese-based nanoenzymes (MB) derived from bovine serum albumin (BSA) through in situ oxidation-reduction reaction, and stimulated RAW 264.7 cells to express integrins (such as LFA-1 and VLA-4) using lipopolysaccharides (LPS). LPS stimulated membranes (LM) modified MB were extracted to prepare a novel macrophage membrane-disguised, manganese-based antioxidant nanoenzyme (MB@LM). In the presence of MB, the absorbance of H2O2 at 240nm showed a time- and concentration-dependent decrease, indicating that MB and MB@LM can effectively catalyze the decomposition of H2O2. In addition, in the presence of H2O2, HK-2 cells were severely damaged, and the cell survival rate decreased to 50.8% ± 4.7%. However, MB treatment restored cell viability in a concentration-dependent manner, reaching 77.0% ± 5.4%, indicating that MB can protect HK-2 cells from oxidative damage. This nanoenzyme can effectively eliminate ROS, alleviate oxidative stress, and inhibit cell apoptosis in a mouse IRI-induced AKI model by simulating the function of natural antioxidant enzymes, thereby reducing kidney damage. By disguising the macrophage membrane, MB@LM can specifically target damaged kidney tissue, increase drug concentration at the lesion site, and enhance therapeutic efficacy. Finally, HE staining was performed on the heart, liver, spleen, and lungs of AKI mice, and no significant differences were found among different treatments. In normal mice, intravenous administration of MB@LM caused no significant weight loss over a 15-day period, and serum biochemical markers remained within normal ranges.. These results indicate that it exhibits good biocompatibility in vivo, with no significant toxicity or adverse reactions and has potential clinical prospects.117 The macrophage membrane-coated nanoenzyme integrates biomimetic inflammation targeting, immune escape, microenvironment response, and multi-enzyme antioxidant and anti-inflammatory design to efficiently overcome the four core bottlenecks of difficult targeting, high off target rate, limited efficacy, and toxicity risk in the treatment of AKI. This biomimetic strategy relies on natural adhesion molecules on the surface of macrophage membranes and inflammatory receptors, which can guide nanoenzymes to accurately homing to ischemic damaged kidney tissue. At the same time, relying on “self recognition” markers such as CD47 on the membrane surface to achieve immune escape significantly prolongs the half-life of circulation in the body and improves the efficiency of lesion enrichment. The outer shell of the cell membrane can protect the catalytic activity of core nanoenzymes such as SOD/CAT/GPx, and directly neutralize pro-inflammatory factors such as TNF-α and IL-1 β, forming a synergistic effect of antioxidant and anti-inflammatory with the broad-spectrum ROS scavenging function of the core. In addition, this modification endows the system with good biocompatibility, effectively reduces systemic toxic side effects, and stably exerts therapeutic effects of protecting renal tubular epithelium, inhibiting cell apoptosis, and promoting renal function repair. In recent years, research has confirmed that this type of biomimetic nanoenzyme exhibits outstanding performance in ROS clearance, inflammation inhibition, renal function protection, and biosafety, providing a safe, efficient, and clinically convertible new paradigm for precision treatment of AKI, with important application potential.116–118 Similarly, Yang et al prepared LiMn2O4 nanoenzymes (LM) with multiple enzyme activities using a hydrothermal method, and prepared cRGD liposomes (cRGD LPs) using a thin film hydration dispersion method to construct a neutrophil-mediated nanoenzyme delivery system – cRGD liposomes loaded with nanoenzymes (LM@cRGD-LPs). Using a mouse unilateral RIRI model and H2O2-induced HK-2 and NRK-52E cell injury models for experiments, it was found that LM@cRGD-LPs By activating the Nrf2/HO-1 signaling pathway, the production of ROS is reduced, thereby alleviating kidney damage and restoring kidney function.119 Jiang et al used self-assembly method to combine curcumin (Cur) with nanocerium using human serum albumin (HSA) to form CeCH nanoenzymes. They found that after treatment with CeCH NPs, the level of H2O2 decreased, indicating that CeCH NPs exhibited higher free radical scavenging activity. CeCH can effectively clear ROS, inhibit iron death in H9C2 cardiomyocytes, and reduce the secretion of inflammatory factors by macrophages. Firstly, CeCH nanoenzyme exhibits strong free radical scavenging ability at low concentrations, effectively reducing iron death and inflammatory cytokine levels. Secondly, by using human serum albumin as a carrier, the water solubility and bioavailability of curcumin were improved, enhancing the targeting ability of the nanoenzyme. In the final experiment, CCK-8 was used to measure myocardial cells, and CeCH did not cause significant toxic reactions, demonstrating good biocompatibility.120 The superiority of CeCH in the treatment of septic heart injury can be explored in the future for its application in septic kidney injury. Metal nanoclusters, with their high surface activity brought by atomic scale size, efficient electron transfer endowed by quantized electronic structure, and artificially designed biomimetic coordination environment, can accurately activate substrates, reduce reaction energy barriers, and mediate redox reactions like natural enzymes, thus exhibiting significant enzyme like catalytic activity.121 In addition, nanoenzymes mainly achieve broad-spectrum ROS clearance by simulating the activity of multiple antioxidant enzymes such as SOD, CAT, GPx, etc. By designing structures with small particle size, oxygen vacancy defects, reversible valence state cycling, etc., active sites are increased, catalytic energy barriers are reduced, and surface modification is used to enhance dispersibility and ROS adsorption capacity. By constructing a multi enzyme cascade catalysis to avoid the accumulation of intermediate products, combined with targeted enrichment and microenvironment response, precise enrichment of damaged sites and enhanced activity under stress conditions can be achieved, with the advantages of high stability and recyclable catalysis, thereby significantly improving the overall ROS clearance efficiency.122 Pt5.65 platinum-based prefabricated nanoenzymes can regulate signaling pathways to improve oxidative inflammatory damage and have good effects on renal distribution and metabolism. Platinum and manganese-based nanoenzymes modified by macrophage membrane have strong targeting ability, high free radical scavenging efficiency, reliable biological safety, and can effectively protect renal tubular cells. Liposomes loaded with manganese-based nanoenzymes can effectively inhibit free radical generation from the source and repair kidney function. Cerium-based composite nanoenzymes have strong free radical scavenging ability and can improve drug solubility, but their renal application research is not yet sufficient. Compared with natural enzymes, nanoenzymes have the advantages of low cost, strong stability, adjustable activity, and easy storage. They can be precisely enriched in damaged kidney tissue through targeted modification, efficiently clearing ROS, regulating related signaling pathways, synergistically exerting antioxidant, anti-inflammatory, and anti-apoptotic effects, reducing renal pathological damage, improving renal function, and most modified nanoenzymes have good biocompatibility and low toxic side effects. They can also be combined with drugs to enhance drug efficacy. However, there are also shortcomings. At present, although nanoenzymes have excellent enzyme-like catalytic activity, there are still significant shortcomings. The lack of catalytic specificity is the core issue. Compared with the precise substrate recognition and specific catalytic ability of natural enzymes, nanoenzymes generally have poor substrate selectivity and are prone to non-specific effects on normal biomolecules in the body, which can interfere with normal physiological metabolism and signaling pathways, and have more obvious off target effects. At the same time, the overall catalytic efficiency is low, and the catalytic activity of most nanoenzymes is far inferior to that of natural proteases. The reaction kinetics are weak, the catalytic rate is limited, and it is difficult to efficiently and continuously remove excess reactive oxygen species. In addition, nanoenzymes are prone to aggregation in the body, and their active sites are blocked by protein adsorption, which further leads to a decline in catalytic activity. Moreover, their valence state cycle is unstable, their ability to adapt to the microenvironment is limited, and they are prone to catalytic deactivation. The accuracy of targeted recognition is insufficient, making it difficult to target the lesion site, ultimately resulting in inefficient and non-specific catalytic activity, which limits their biological application effectiveness.49,123,124 Nanoparticles Disguised by Membrane Nanoparticles disguised by cell membranes are formed by wrapping specific types of cell membranes around the surface of nanoparticles. This synthesis method endows nanoparticles with a series of biological properties, such as immune escape, cell targeting, and biological barrier penetration ability.71 Unlike polymer materials, cell membranes are natural biomaterials with biocompatibility advantages. Nanoparticles encapsulated by cell membranes exhibit diversity, as the coating film can originate from any cell, such as platelets, cancer cells, stem cells, immune cells, etc.125 Nanoparticles disguised as cell membranes were first proposed in 2011, and researchers used red blood cells as a source of membrane material. It was found that nanoparticles coated with red blood cell membranes exhibited significantly prolonged circulation time in mice, which is of great significance for applications that require long-term drug release. The use of natural red blood cell membranes as surface modifications can reduce immune system recognition and clearance, and improve the biocompatibility of nanoparticles. This method not only prolongs the circulation time of nanoparticles, but also preserves the natural functions of red blood cell membranes, such as the presence of immunosuppressive proteins, providing the possibility for personalized medicine. This method can also be extended to other nanostructures, such as silicon nanoparticles and quantum dots, with broad application prospects.126 Liu et al used single lotion technology to wrap coenzyme Q10 (CoQ10) in polyethylene glycol polylactic acid (PEG5K-PLA10K) and prepared a kind of coenzyme Q10 nanoparticles (NPCoQ10) wrapped by neutrophil membrane. Using a renal I/R injury model and human renal epithelial cells, studies have shown that after treatment with N-NPCoQ10, the levels of inflammatory cytokines in the kidneys of I/R injured mice are significantly inhibited, and the activities of two important antioxidants, SOD and GSH, are significantly increased. Moreover, MDA (a marker of oxidative stress) was significantly reduced in the N-NPCoQ10 treatment group, indicating that N-NPCoQ10 significantly reduced oxidative stress, inhibited cell apoptosis, weakened inflammatory response, and thus improved renal function.127 In addition, Ba et al prepared hollow mesoporous manganese dioxide nanoparticles coated with engineered M2 macrophage membranes (M2M) and targeted peptide modifications (KM@M @M NPs). Research finds KM@M @The M NPs group significantly reduced renal MDA levels and increased renal total antioxidant capacity. KM@M @M NPs treatment can also inhibit the activation of NLRP3, reduce the expression levels of cleaved Caspase-1 and GSDMD-N, KM@M @M NPs can inhibit calcium oxide induced renal cell death. It can specifically target damaged renal tubules, reduce the distribution of drugs in non-target tissues, and lower systemic toxicity KM@M @M NPs combine antioxidant and anti-inflammatory functions, capable of simultaneously clearing ROS and inhibiting NLRP3 inflammasome activation, providing more comprehensive protection.128 This study expands the application of engineered cell membranes in nanomedicine and provides new strategies for the treatment of kidney stones. In the future, it can be applied in RIRI to verify whether it can alleviate renal injury caused by ischemia-reperfusion. Zhang et al designed MCM@MOF @Irisin nanoparticles utilize macrophage membranes to achieve immune escape and target accumulation in IRI kidneys. In an acidic microenvironment, the MOF framework disintegrates, releasing irisin, which activates mitochondrial biogenesis and antioxidant pathways, enhances superoxide dismutase 2 activity, reduces ROS production, significantly reduces serum creatinine and blood urea nitrogen, and repairs mitochondrial function, thereby reducing renal tubular injury.49 The core advantage of this study lies in the construction of a dual functional system of “macrophage membrane encapsulation + MOF carrier”, which not only utilizes the natural biomimetic properties of macrophage membranes to achieve in vivo immune escape and prolong the half-life of nanoparticle circulation, but also utilizes the acidic responsiveness of MOF materials to achieve precise controlled drug release. At the same time, it targets the mitochondrial biogenesis pathway, filling the research gap of “immune escape targeted drug delivery mitochondrial repair” integration in RIRI intervention, and providing new design ideas and technical support for RIRI’s mitochondrial targeted therapy. The strategies of cell membrane camouflage and biomimetic coating modification can significantly enhance the therapeutic targeting and biological application performance of nanoparticles through multiple mechanisms such as homologous targeting, immune escape, biological adhesion, receptor ligand recognition, and microenvironment chemotaxis. This strategy mainly uses natural cell membranes such as red blood cells, macrophages, tumor cells and stem cells to wrap nanocarriers, which can endow nano-source cells with complete surface facial mask proteins, glycocalyx and adhesion molecules, which can not only simulate the homologous recognition characteristics of source cells, achieve targeted homing and precise enrichment of homologous pathological tissues, but also effectively shield the physical and chemical signals of the nanoparticles themselves, reduce the non-specific clearance of the reticuloendothelial system, effectively extend the circulation time of the carrier in vivo, and reduce the accumulation of normal tissues off target. At the same time, functional molecules such as integrins, chemokine receptors, and adhesion proteins on the surface of cell membranes can specifically bind to ligands highly expressed in pathological sites such as inflammation, tumors, and ischemic injury, achieving efficient active targeted recognition. Compared to traditional artificially synthesized modified carriers, the cell membrane camouflage system has better biocompatibility and lower immunogenicity, and can stably target lesion areas in complex physiological environments.117,129 Among them, neutrophil and macrophage membranes have natural inflammatory homing ability, and their targeted enrichment effect on severe inflammatory RIRI is significantly better than that of red blood cell membrane carriers. M2 macrophage membranes not only have efficient inflammatory targeting ability, but also actively regulate the immune balance of the body, promote damaged tissue repair, and have more prominent functional advantages. However, there are still significant shortcomings in the preparation of cell membrane disguised nanoparticles at present, and the core bottleneck lies in the cell membrane extraction process. Common extraction methods such as low-permeability lysis, repeated freeze-thaw, ultrasound, and homogenization all have defects. Low-permeability lysis has low extraction efficiency and is only suitable for a few cell types such as red blood cells. Repeated freeze-thaw can easily damage the activity of membrane proteins, while the heat generated by ultrasound can damage the overall integrity of the cell membrane.72 This greatly limits the efficient and stable preparation and large-scale application of this type of nanocarrier. Therefore, there is an urgent need to develop new technologies for cell membrane extraction that are easy to operate, efficient, and high-quality, improve the synthesis system of cell membrane disguised nanoparticles, and further promote their biomedical translational applications in the future. Extracellular Vesicles Extracellular vesicles mainly include exosomes, microvesicles, and apoptotic bodies, secreted by stem cells, renal tubular epithelial cells, macrophages, etc. They carry signaling molecules such as mRNA, miRNA, proteins, lipids, and mitochondrial fragments, and regulate inflammation, oxidative stress, cell apoptosis, proliferation and regeneration, fibrosis, and angiogenesis through paracrine secretion and intercellular communication. They participate in the repair of AKI and delay the progression of CKD.130 Extracellular vesicles, with their natural biofilm structure and endogenous cargo loading properties, can efficiently mediate the intercellular delivery of functional microRNAs, proteins, and lipid signaling molecules. By regulating apoptosis-related signaling pathways, excessive apoptosis of renal tubular epithelial cells is inhibited, while activating angiogenesis-related molecular pathways, inducing neovascularization, improving local microcirculation, and exerting anti-inflammatory, antioxidant, and tissue damage repair and remodeling effects. EVs play an important role in intercellular communication, organ homeostasis, and disease development. Among them, exosomes, as a subgroup of EVs, have a diameter of about 100 nanometers. The composition of exosomes is diverse, including nucleic acids, proteins, lipids, amino acids, and metabolites, which can reflect the characteristics of their source cells. In recent years, the role of extracellular vesicles in various diseases has gradually received attention, and their potential in disease diagnosis and treatment has also gradually emerged.131 In the kidney, EVs are closely related to processes such as inflammation, fibrosis, thrombosis, cell adhesion, immune suppression, as well as growth and regeneration.132 Zou et al isolated human umbilical cord mesenchymal stem cells (huMSCs) from the human umbilical cord and cultured them in the absence of fetal bovine serum to collect EVs. Using a rat unilateral RIRI model and renal tubular epithelial cells for experiments, it was found that EVs secreted by huMSCs reduced renal injury induced by ischemia-reperfusion by promoting angiogenesis.133 Similarly, Huang et al used human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC exos) to deliver miR-29a-3p, targeting type I collagen in fibroblasts and tumor necrosis factor receptor 1 in endothelial cells to treat renal fibrosis and vascular rarefaction after renal ischemia-reperfusion injury.134 However, it lacks unified preparation and quality control standards, making it difficult to produce on a large scale and restricting clinical translation. Moreover, there are differences in MSCs from different donors and batches, which can lead to unstable biological functions and therapeutic effects. Liu et al isolated EVs from human placental MSCs and used a mouse RIRI model to inject EVs (Col EVs) encapsulated in collagen matrix into the left renal cortex within 5 minutes after reperfusion. The CCK-8 experiment showed that EVs promoted the proliferation of HK-2 cells at 24 and 48 hours. Scratch tests showed that Col EVs stimulation significantly increased cell migration, and compared to other groups, Col EVs treatment significantly reduced DNA damage. These findings suggest that Col EVs can enhance cell protection by inhibiting apoptosis pathways and DNA damage. Moreover, EVs labeled with Gaussian luciferase (Gluc) were internalized by HK-2 cells, and the Gluc signal increased over time. Experiments have shown that encapsulating EVs in injectable collagen matrix increases their retention and stability in vivo, and further enhances their therapeutic efficacy in mouse models.135 Lopes et al isolated EVs from adipose tissue derived from mesenchymal stem cells and used rat I/R model and human renal proximal tubular cells. The study found that EVs can restore the normal redox state of mitochondria by reducing the production of superoxide anions in mitochondria. Although EVs can improve mitochondrial function, within 24 hours of reperfusion, EVs did not significantly improve the expression of acute injury markers in the kidneys (such as KIM-1 and NGAL), nor did they significantly improve renal function (serum urea and creatinine levels). However, in the early stage of apoptosis, EVs were able to partially reverse the apoptosis process of renal proximal tubular cells under hypoxic conditions.136 Xie et al isolated bone marrow mesenchymal stem cells (BMSCs) from 4-week-old C57BL/6 mice and cultured them in vitro. EVs were isolated from MSCs by density gradient centrifugation to prepare EVs derived from MSCs overexpressing tryptophan 2,3-dioxygenase (IDO) (MSC Exo IDO). In the RIRI mouse model, injection of MSC Exo IDO via tail vein showed that mice treated with MSC Exo IDO exhibited faster renal function recovery, lower Scr and BUN levels, less tubular injury, and less cell apoptosis. It also promoted polarization of M1 macrophages towards M2 macrophages, reduced secretion of inflammatory factors, and enhanced anti-inflammatory response.137 Wang et al also extracted extracellular vesicles from bone marrow-derived mesenchymal stem cells (BMSCs). The study showed that compared with the control group, the BMSCs group significantly inhibited the expression of Caspase-3 and Bcl-2 related proteins, highlighting the significant protective effect of BMSCs on I/R-induced apoptosis of NRK-52E cells. This protective effect was most significant in the early stage of reperfusion (4–8 hours in vitro and 8–16 hours in vivo).138 The study provides a new mechanism for BMSCs to protect the kidneys in the early stages of I/R injury by secreting BMexos, and provides a theoretical basis for the development of novel therapeutic strategies based on BMexos. Yuan et al induced differentiation of human induced pluripotent stem cells into human induced pluripotent stem cell-derived mesenchymal stem cells (hiPSC MSCs), isolated EVs from hiPSC MSCs, and conducted experiments using a rat kidney I/R injury model and HK-2 cells. It was found that hiPSC MSCs EVs could dose-dependently enhance the proliferation ability of HK-2 cells under H/R injury conditions. Both in vivo and in vitro experiments have shown that hiPSC MSCs EVs can reduce MDA content, increase SOD activity, and mainly exert protective effects by inhibiting necrosis rather than apoptosis. In summary, this study demonstrates that hiPSC MSCs EVs exert a protective effect against renal I/R injury by delivering SP1 to renal cells, activating SK1 expression and S1P generation, thereby inhibiting necrosis.139 The role of SP1 in hiPSC MSCs EVs was clearly validated using CRISPR/Cas9 gene editing technology and adenovirus mediated gene overexpression technology, enhancing the reliability of the research conclusions. However, the specific application and effectiveness of hiPSC MSCs EVs in human kidney diseases have not been clinically validated, and the long-term effects of hiPSC MSCs EVs, as well as their distribution, metabolism, and other dynamic processes in kidney tissue, lack in-depth research. These factors may affect the feasibility and effectiveness of their clinical prospects. Ranghino et al isolated glomerular mesenchymal stem cells (Gl MSCs) and T-CD133+ cells from surgically resected kidneys, and isolated EVs from the culture supernatant of Gl MSCs and T-CD133+ cells. Using mouse model experiments, the study showed that Gl MSCs and their extracellular vesicles (Gl MSC EVs) were evenly distributed in the renal tubules, and Gl MSC EVs regulated various biological processes such as nucleic acid metabolism, cell communication, and gene expression through their specific miRNA expression to promote renal repair.140 In addition, Salybekov et al isolated peripheral blood mononuclear cells from healthy human subjects and cultured them in a specific growth factor medium for 7 days to obtain regeneration associated cells (RACs). EVs were isolated from RACs and treated with tail vein injection of RACev in a rat RIRI model. The study found that compared with the control group, systemic injection of RACev significantly reduced serum creatinine and hematuria nitrogen on the third day. Histologically, compared with the control group, the treatment group had less fibrosis in the cortical and medullary regions. CD31 staining confirmed that the capillary density of the treatment group increased compared to the control group. The research results confirm that RACev can improve kidney function and alleviate kidney damage by delivering miRNAs that are anti-inflammatory, anti-fibrotic, and anti-apoptotic.141 Dominguez et al extracted renal tubular cells from human kidneys and isolated their extracellular vesicles. Establish RIRI model using nude mice. Research has found that rats injected with human exosomes have normal serum creatinine levels after 48 hours of reperfusion. Untreated renal ischemia can lead to extensive damage and loss of renal microvessels. Intravenous injection of human renal tubular cells or their extracellular vesicles can significantly improve kidney function and structure 24 hours after RIRI, thereby preventing further deterioration of kidney injury.142 However, its specific mechanism and long-term effects are still unknown, and the study used an immunodeficient nude mouse model, which may not fully reflect the therapeutic effect in immunocompromised animals or humans. In addition, Cheng et al prepared oxygen-sensitive macrocyclic amphiphilic molecules (C5A) through chemical synthesis and combined them with commercial dye phthalocyanine (Pc) to form Pc/C5A complexes. The Pc/C5A complex was co-incubated with extracellular vesicles (MSC EVs) secreted by mesenchymal stem cells, and unbound components were removed by ultracentrifugation to construct a novel nanoscale hypoxia sensitive co assembly (Pc)/C5A@EVs). TECs were used for in vitro experiments, and RIRI mouse models were used for in vivo experiments. Pc was injected through the tail vein/C5A@EVs. The study found that it exhibits good hypoxia-sensitive imaging ability both in vitro and in vivo and can specifically release Pc under hypoxic conditions, achieving near-infrared fluorescence imaging. In the mouse model, Pc/C5A@EVs significantly reduced serum levels of SCr and BUN, alleviated pathological damage to kidney tissue, and promoted the recovery of kidney function. In vitro Pc/C5A@EVs, by inhibiting the expression of HIF-1 α and downstream NF-κB signaling pathway in TECs, induced M1 macrophages to transform into M2 macrophages, exerting anti-inflammatory and renal repair effects.143 The construction method of this co-assembly is simple, and the materials used (such as MSC EVs) have certain clinical prospects, providing potential clinical translational value for the diagnosis and treatment of kidney diseases in the future. Extracellular vesicles mediate intercellular signal communication and carry active substances such as proteins and microRNAs. These findings mainly alleviate local renal inflammation by inhibiting pathways such as NF-κB and NLRP3, regulate macrophage polarization towards anti-inflammatory phenotype, activate the Nrf2 pathway to clear reactive oxygen species, alleviate oxidative stress, downregulate apoptosis-related proteins to reduce apoptosis of renal tubular epithelial cells, and activate pathways such as PI3K/Akt to promote proliferation and regeneration of renal tubular epithelial cells, repair damaged renal parenchyma. They also inhibit epithelial mesenchymal transition and renal interstitial fibrosis mediated by the TGF β/Smad pathway. They can promote renal microvascular regeneration and improve renal microcirculation, thereby synergistically exerting a multi-target effect on renal injury repair and delaying the progression of acute renal injury to chronic kidney disease.73,144 Extracellular vesicles (EVs) are currently the safest and most clinically applicable natural nanocarriers. Umbilical cord and placental derived MSC EVs have the best ability to promote angiogenesis and tissue repair, and their therapeutic effect is significantly better than that of adipose derived MSC EVs (Table 4). Functional EVs modified by genetic engineering can target the delivery of repair genes and proteins, with much higher efficacy than natural unmodified EVs, but the preparation process is complex and costly. Renal tubular homologous EVs have the strongest renal targeting specificity, but their raw material sources are scarce and cannot be mass-produced. Overall, in terms of safety, extracellular vesicles have significantly better safety than stem cell therapy due to their lack of autonomous proliferation ability, extremely low tumorigenic risk, weak immunogenicity, and no risk of ectopic colonization. Stem cells pose potential risks such as tumorigenicity, immune rejection, infusion reactions, and abnormal cell colonization. In terms of effectiveness, stem cells have both cell differentiation and regeneration as well as paracrine functions and have a stronger ability to repair severe tissue damage, but the efficacy varies greatly among individuals. Extracellular vesicles mainly exert anti-inflammatory, antioxidant, and reparative effects through signaling molecules, with good targeting, fast onset, and high batch stability. However, they lack cell regeneration ability and are more suitable for mild-to-moderate injury and precise regulation.145,146 In summary, extracellular vesicle therapy avoids the immune rejection and ethical issues that traditional stem cell therapy may cause, and is a “cell-free” treatment strategy. Compared with traditional cells, extracellular vesicles have more stable biological activity, are easier to preserve and standardize for extraction. Meanwhile, extracellular vesicles exert therapeutic effects through various mechanisms, such as carrying specific miRNA activation signaling pathways, and have broad therapeutic potential. It also modifies MSCs through genetic engineering to enhance therapeutic efficacy, providing the possibility for personalized treatment.73 However, the clinical translation of EVs therapy still faces many challenges, such as unclear biosynthesis and uptake mechanisms of EVs, lack of standardized drug production quality management standards and difficulty in penetrating the physiological barrier of the kidneys. Further research is needed in the future on the preparation, functionalization, and characterization techniques of EVs, as well as optimizing their application in the treatment of kidney diseases.74 Table 4Comparison of Mesenchymal Stem Cell–Derived Extracellular Vesicles from Different SourcesTypeSourceAdvantageDeficiencyReferencesMesenchymal stem cell-derived EVsAdipose tissueEasy access, abundant source, minimally invasive, unlimited in vitro cultureOnly reverses early apoptosis, low extraction efficiency[136,147]Mesenchymal stem cell-derived EVsBone marrowSignificant anti-inflammatory and renal repair effectsDifficult to obtain, affected by donor age[148,149]Mesenchymal stem cell-derived EVsUmbilical cordLow immunogenicity, non-invasive collection, obvious pro-angiogenesis effectNeed to confirm donor health status[133,134]Mesenchymal stem cell-derived EVsHuman induced pluripotent stem cellsStrong immune regulation, high proliferation and differentiation abilityUnclear long-term effects and clinical outcomes[139,150] Table 4Comparison of Mesenchymal Stem Cell–Derived Extracellular Vesicles from Different SourcesTypeSourceAdvantageDeficiencyReferencesMesenchymal stem cell-derived EVsAdipose tissueEasy access, abundant source, minimally invasive, unlimited in vitro cultureOnly reverses early apoptosis, low extraction efficiency[136,147]Mesenchymal stem cell-derived EVsBone marrowSignificant anti-inflammatory and renal repair effectsDifficult to obtain, affected by donor age[148,149]Mesenchymal stem cell-derived EVsUmbilical cordLow immunogenicity, non-invasive collection, obvious pro-angiogenesis effectNeed to confirm donor health status[133,134]Mesenchymal stem cell-derived EVsHuman induced pluripotent stem cellsStrong immune regulation, high proliferation and differentiation abilityUnclear long-term effects and clinical outcomes[139,150] Comparison of Mesenchymal Stem Cell–Derived Extracellular Vesicles from Different Sources Injectable Hydrogel Hydrogels have an insoluble three-dimensional polymeric structure, which is characterized by high biocompatibility, biodegradability and high absorption, so they are used for in vivo delivery of drugs, nucleic acids and cells.151 Although mesenchymal stem cell-derived extracellular vesicles (MSC EVs) have shown great potential in tissue repair, their therapeutic efficacy is limited by rapid clearance in vivo and short half-life. To overcome this problem, researchers have developed a sustained-release strategy based on hydrogel to enhance the therapeutic effect of EVs.152 Zhou et al prepared kidney extracellular matrix (ECM) through improved acellular and gel strategies, made kidney ECM into hydrogel, separated adipose derived mesenchymal stem cells (ad MSCs) from rat epididymal adipose tissue, established IRI model through renal artery occlusion, and injected ad MSCs and extracellular matrix hydrogel (ECMH) into the kidney before reperfusion Compared with the Sham group, the IRI group showed significant increases in SCr and BUN at 24 and 72 hours after reperfusion. 24 hours after transplantation of ad MSCs with or without ECMH, the levels of SCr and BUN significantly decreased. The ECMH+ad MSCs group showed a significant decrease in the following 72 hours. Experiments showed that ECMH can significantly reduce oxidative stress and cell apoptosis, promote the proliferation, secretion, and epithelial differentiation of ad MSCs, and act as a sustained-release scaffold to facilitate cell migration. The immunohistochemical results showed that compared with natural kidneys, ECM had almost no significant expression of MHC-I protein, indicating that the ECM prepared in the study had low immunogenicity. In addition, HE staining results showed that the ECMH range gradually decreased over time, and there was no significant increase in cell infiltration inside or around ECMH. The Taipan Blue test showed that there was no significant difference in cell survival rate between the normal group and ECMH co-culture group in human renal tubular epithelial cells and human glomerular microvascular endothelial cells.153 As an injectable stent, renal ECMH can significantly improve the retention and survival rates of transplanted ad MSCs in damaged kidneys, reduce the proportion of them escaping to other organs, and enhance the therapeutic effect of ad MSCs on renal IRI. In addition, Liu et al developed an injectable self-assembled peptide/heparin (SAP/Hep) hydrogel, which uses the kidney I/R model Research shows that SAP/Hep hydrogel can achieve sequential-release kinetics, enabling rapid release of anti TNF-α and continuous release of HGF. Compared with the I/R and free drug groups, the SAP drug group showed a significant decrease in neutrophil gelatinase-related lipocalin (a biomarker of renal tubular injury) in the kidneys. SAP/Hep hydrogel has good biocompatibility and does not cause kidney inflammation or damage. Therefore, as a drug delivery platform, SAP hydrogel has significant potential in tissue repair.154 Similarly, Zhao et al designed and synthesized a carrier based on self-assembled peptides (SAP) for slow release of mitochondrial targeted antioxidant (Mito TEMPO, MT) to enhance its long-term therapeutic effect on AKI. Research has shown that SAP-MT improves IRI through its prolonged mitochondrial protective effect, thereby improving the long-term outcomes of AKI.155 In addition, Soranno et al encapsulated MSCs in hyaluronic acid (HA) hydrogel, and developed an injectable hydrogel based on HA, which is used to locally and continuously release IL-10 to alleviate local and systemic inflammatory reactions after AKI and reduce subsequent fibrosis. Studies have shown that MSCs encapsulated in HA hydrogel can significantly reduce the level of neutrophil gelatinase-related lipid carrier protein in urine, indicating that it has potential in reducing kidney damage. Compared with the untreated control group, the MSC/HA treatment group showed better renal function one month after bilateral ischemia-reperfusion injury. In addition, proteomic analysis showed that the kidneys treated with MSC/HA had protein expression closer to uninjured kidneys, indicating its positive role in reducing inflammation and fibrosis. However, the study found that when IL-10 and HA hydrogel were locally injected into the left kidney under the capsule, although there was improvement in some aspects, the degree of fibrosis of the left kidney increased. This indicates that in treatment, the combination of drugs and carriers may produce antagonistic effects, affecting the therapeutic effect. In addition, local injection into the left renal capsule may cause additional mechanical damage or interference to the kidneys, thereby affecting the therapeutic effect.75 Najafi et al designed a new integrin receptor-binding nanofiber peptide hydrogel (FmocFF+FmocRGD SNAP), which is used to bind human umbilical cord mesenchymal stem cells (WJ MSCs) for treatment and nitric oxide delivery to treat RIRI. The research results indicate that local injection of FmocFF+FmocRGD SNAP/WJ MSCs in a mouse model can significantly improve the survival rate of transplanted WJ MSCs and promote the expression of endothelial related genes in WJ MSCs, thereby promoting angiogenesis and regeneration of ischemic tissues. However, further research is needed to determine the role of other renal endpoints and biomarkers in renal I/R injury.151 In conclusion, due to its good biocompatibility, degradability and porous structure, hydrogel can achieve local drug delivery and drug slow release in situ, accurately act on damaged renal tissue, continuously eliminate reactive oxygen species, inhibit inflammatory pathways, protect renal tubular epithelial cells, and block the progression of acute renal injury to chronic kidney disease. The injectable nano functional hydrogel delivery system also has the advantages of long-term sustained release, in situ retention, microenvironment regulation and targeted enrichment of renal tissue. For example, injectable hydrogel forms a three-dimensional porous network through in situ cross-linking after injection, physically encapsulates drugs, stem cells or extracellular vesicles, restricts their free diffusion by virtue of the network structure, and relies on tissue adhesion to resist blood flow erosion, reducing the rapid removal of therapeutic agents by the body. Its controllable degradation characteristics can achieve drug sustained release, and the three-dimensional microenvironment can protect the stability of the active substance, thereby significantly prolonging the local retention time of the therapeutic agent at the site of kidney injury and increasing the local effective concentration.156,157 Compared with traditional-free drugs and ordinary carriers, it can effectively improve the problems of rapid clearance, non-specific enrichment, low renal targeting efficiency, and insufficient local action time of drugs, stem cells, or extracellular vesicles. At the same time, it can co-load multiple types of active substances, improve stability and long-term release efficiency, and compensate for the shortcomings of single treatment methods. At present, there are still many limitations in this field: insufficient mechanical properties of hydrogels, limited local retention time, and poor matching between degradation and drug release. Research is mostly limited to modeling unilateral renal ischemia-reperfusion injury in mice, lacking support from large animal and comorbidity models. The explanation of renal protection-related signaling pathways and molecular mechanisms is not deep enough. Lack of material compatibility, formulation standardization, drug administration standards, and long-term safety evaluation, with prominent barriers to clinical translation. In the future, we can build ROS/pH responsive hydrogels, regulate particle size and morphology, fixed-point modify target groups, design multi-drug sequential-release systems, improve large animal validation and mechanism analysis, optimize mass production preparation processes, break through the barrier between basic research and clinical application, and provide new ideas for precise treatment of renal ischemia-reperfusion injury. Conclusion and Outlook Existing research has shown significant progress in the application and mechanism research of nanomedicine in renal ischemia-reperfusion injury, especially in targeted drug delivery, anti-inflammatory and antioxidant treatments. The addition of nanocarriers can alleviate the toxic side effects of single drugs and avoid their limitations. However, the urgent issue now is that most nanomedicine treatment research has not yet been translated into clinical practice, and still faces problems such as unclear mechanism exploration, complex nanocarrier production, good biocompatibility and precise targeting. Next, there is still a lot of research work to be done on the application of nanomedicine in renal ischemia-reperfusion. Clinical Limitations of RIRI Animal Models First of all, most of the existing studies still stay on animal experiments. In the study of renal ischemia reperfusion, most of the rats or mice are used, most of them are male. Human RIRI patients are mostly accompanied by basic diseases (such as diabetes, hypertension, chronic kidney disease). These basic diseases will lead to abnormal renal microcirculation and elevated levels of oxidative stress, which are essentially different from the physiological state of the kidney of healthy animals. Moreover, clinical patients cover different age levels. The physiological decline of the kidney function of elderly patients, and the kidney metabolism of young patients are strong, while experimental animals are mostly young adults, which cannot reflect the age-related differences in renal function. Animal models can only simulate “simple RIRI” and cannot replicate the complex pathological features of human RIRI in clinical practice, which results in animal models being unable to fully simulate human pathological states. Dhanesha et al used a mouse stroke model to investigate the mechanism of multipotent protein muscle-type pyruvate kinase 2 in ischemic stroke. Two different stroke models were used in the experiment, and the effects of gender and hyperlipidemia were studied to improve the clinical relevance of the study.158 So in the future, research on renal ischemia-reperfusion can also try to incorporate gender, underlying diseases, and age conditions to better fit the clinical human disease status. Biosafety Bottleneck and Renal Clearance Design of Nano Drug Delivery Systems Secondly, some nanocarriers have potential biological toxicity. For example, some unoptimized nanomedicines may affect the normal physiological functions of cells and even lead to cell death. This is particularly crucial in organs such as the kidneys that are highly dependent on cellular function, and may counteract their therapeutic effects.159 Moreover, the physiological and pathological states of different individuals may affect the targeting performance of nanocarriers. For example, differences in kidney function, inflammatory status, and immune response among patients may lead to significant variations in the distribution and effectiveness of nanocarriers in different individuals.61 Although the addition of nanomedicine has improved the targeting of drug therapy and expanded more directions for the treatment of renal ischemia-reperfusion. However, some nanomedicines still need to be further optimized to improve biocompatibility and reduce toxic side effects during treatment. In the future, surface modification (such as polyethylene glycol) can be used to reduce the immune response of nanoparticles. Toxicity can be reduced by controlling the size, shape, and charge of nanoparticles, or the toxicity of nanoparticles can be reduced through “safe design” methods such as doping with iron elements.160 After injecting nanomedicine, the liver is the most important organ in the body that first intercepts nanocarriers, and it is also the biggest challenge for systemic delivery. Kupffer cells (macrophages) in the liver quickly recognize and engulf exogenous nanoparticles, causing most drugs to be intercepted and enriched by the liver before reaching the target site. The reticuloendothelial system (RES) passively captures nanomaterials, resulting in drug accumulation in the liver and spleen, insufficient drug dosage in target tissues, and decreased therapeutic efficacy. Long-term accumulation can also cause liver toxicity, inflammation, and metabolic burden, greatly limiting the clinical safety of nanomedicine. Therefore, reducing liver phagocytosis and prolonging systemic half-life are the core prerequisites for effective systemic delivery of nanomedicine. To avoid liver uptake, nanoparticles can be reduced in liver retention by adjusting the appropriate particle size range, surface hydrophilic modification (PEG, zwitterionic, cell membrane coating), reducing protein adsorption, avoiding immune recognition, and reducing macrophage phagocytosis to achieve long circulation, allowing nanoparticles to stay in the bloodstream for longer periods of time and reducing liver interception.161 After liver interception is effectively reduced, the ultimate destination of nanomedicine is mainly renal filtration and excretion, which is also the safest and most ideal metabolic pathway. Nanoparticles with a particle size less than the glomerular filtration threshold (usually less than 6 nm) can smoothly pass through the glomerulus and be excreted through urine without long-term accumulation in the body. And the nanocarrier will gradually decompose into small molecular fragments, no longer retained by the liver, and will not cause long-term residues in the body, reducing chronic toxicity from the root. Renal clearing nanomedicine can prevent liver and spleen accumulation poisoning, reduce inflammation and organ damage caused by long-term material deposition, and conform to the normal metabolic pathway of the human body. Its safety is much higher than that of accumulating nanomedicine in reducing systemic toxic side effects and improving clinical translational feasibility.162–164 The primary challenge of systemic administration of nanomedicine is excessive uptake by the liver. Only by achieving long circulation and avoiding immune phagocytosis can the drug be delivered to the lesion. On this basis, allowing drug carriers and metabolic byproducts to be smoothly filtered and cleared by the kidneys is the key to solving the residual and long-term safety of nanomaterials in the body. Nanodrugs with long circulation and renal clearance can not only avoid liver interception and improve efficacy, but also be completely excreted from the body through the kidneys, with lower toxic side effects and the best clinical application prospects. They are also the mainstream direction of nanomedicine development at present. Nanocarrier Targeting Strategy and Functional Modification Nanoparticles, with their unique physicochemical properties, controllable delivery efficiency, and good biocompatibility, have become the core carrier for intervening in renal ischemia-reperfusion injury (RIRI). Their core logic is to deliver antioxidant, anti-inflammatory, and other drugs to damaged kidney tissue through precise targeting and intelligent functional design, improving therapeutic efficacy and reducing systemic toxic side effects. At present, its core strategies include passive targeting, active targeting, and multifunctional modification, which synergistically enhance the targeting and safety of RIRI therapy, as follows: The physical and chemical properties of nanoparticles, such as particle size, surface charge, and density, are the core determinants of their in vivo biological distribution, circulation retention ability, and passive-targeting efficiency of RIRI lesions. Passive targeting, as the basic enrichment strategy for kidney targeted nanomedicine, mainly relies on the synergistic regulation of RIRI pathological microenvironment characteristics and the physicochemical properties of nanoparticles to achieve specific enrichment of damaged kidney tissue. RIRI can cause microvascular endothelial damage and abnormal increase in vascular permeability around the glomerulus and renal tubules. Nanoparticles can achieve lesion leakage and retention through EPR effect, and local inflammation mediated blood flow redistribution can further enhance their renal enrichment effect. Among the key physicochemical parameters, particle size can directly determine the renal accumulation and metabolic clearance efficiency by regulating the ability of nanoparticles to cross biological barriers, evade reticuloendothelial system clearance, and glomerular filtration. Nanoparticles with a particle size <6 nm can be rapidly filtered through the glomerulus and cleared with urine, resulting in extremely low renal tissue accumulation. 6–20 nm particles can effectively retain and enrich in renal tissue, with a significantly delayed clearance rate. Particles with a diameter greater than 20 nm are difficult to pass through the glomerular filtration barrier, resulting in a significant decrease in renal targeting.165,166 Surface charge also affects the targeting efficacy of nanomedicine. Nanoparticles with near neutral or weak negative charge can effectively reduce non-specific protein adsorption in vivo and decrease normal tissue accumulation.167 In addition to size and charge, the density differences of nanoplatforms also independently regulate their biological distribution, clearance rate, and targeting efficiency: high-density nanoplatforms can rely on stronger buoyancy to approach the blood vessel wall, improve renal tissue permeability and enrichment ability, and reduce clearance rate,168 while low-density nanoparticles have faster blood circulation and higher renal clearance efficiency, significantly weakening the targeting effect.169,170 For example, low-density silica nanoparticles have less renal accumulation and higher excretion efficiency, while high-density gold nanoplatforms can significantly improve renal targeting and delay clearance. In addition, the endothelial translocation of glomeruli can assist nanoparticles in breaking through the vascular barrier, further enhancing their renal tissue permeability efficiency.171 Accurately optimizing the physicochemical parameters such as particle size, surface charge, and density of nanoparticles can effectively improve their in vivo circulation stability, enhance the passive enrichment effect of damaged kidney tissue under pathological conditions, and reduce non-specific accumulation in normal organs. This is the core design strategy for enhancing the therapeutic efficacy of RIRI targeted nanomedicine. Active targeting solves the problem of insufficient specificity in passive targeting by modifying specific ligands on the surface, accurately targeting key RIRI target cells. Short amino acid repeat peptides, single amino acid modifications, or prodrug-like surface modifications can promote the transport of carriers through glomerular endothelium through active cross cellular pathways rather than passive size-dependent filtration. For example, enzyme activated dendritic drug conjugates respond to gamma-glutamyl transpeptidase (GGT), a brush edge enzyme enriched in the glomerulus that can achieve site-specific drug activation and effective glomerular delivery through receptor-mediated translocation, thereby overcoming physiological filtering barriers.172 Similarly, serine modified nanocarriers have been shown to enhance glomerular accumulation while reducing liver uptake, highlighting the critical role of trace amino acid motifs in regulating endothelial transport behavior.173,174 Among classic ligands, TIP peptide,175 λ light chain,176 and others target glomerular endothelin and renal tubular epithelial cells, respectively. Hyaluronic acid targets CD44+pro-inflammatory macrophages with both targeted and anti-inflammatory effects.176 Biomimetic encapsulation of cell membranes can achieve homologous recognition and evade immune clearance. Kim et al developed engineered extracellular vesicles (pSEVs) derived from mesenchymal stem cells modified with polyethylene glycol hyaluronic acid. Targeted renal accumulation was achieved through the interaction between HA-CD44 and HA Toll-like receptor 4, significantly reducing renal dysfunction markers.177 Although active targeting strategies have improved specificity, there are still some inherent limitations. Firstly, ligand or peptide modifications may increase immunogenicity and accelerate systemic clearance. Secondly, many active targeting pathways rely on endocytosis, which may lead to lysosomal degradation of encapsulated biological agents such as proteins or nucleic acids, thereby affecting therapeutic efficacy. Active targeting rarely overcomes the basic limitations imposed by passive targeting of the kidneys.178,179 Therefore, passive and active targeting should not be viewed as independent strategies, but rather as interdependent designs that must be optimized together. Functional modification can be combined with RIRI’s high ROS, acidic, and inflammatory enzyme enriched microenvironment to achieve intelligent drug release and multiple protections. Surface functionalization (such as amino acid modification) can regulate surface properties, assist in antioxidant activity, and reduce immunogenicity. Nano-prodrugs are activated by enzymatic hydrolysis/ROS stimulation in the damaged area, and polymers (such as poly - β - aminoesters) are pH sensitive for targeted NAC delivery.180 Elevated levels of glutathione (GSH) trigger disulfide bond cleavage in carriers such as PEG-SS-PLGA, as well as overexpression of enzymes such as MMP-2/9, allowing peptides to cleave and release drugs.181 ROS/pH/enzyme sensitive bond design achieves targeted drug release, improving utilization efficiency and systemic toxic side effects. PLGA, liposomes and other degradable carriers combined with hydrophilic modification can balance long circulation and safe metabolism, avoid liver accumulation toxicity, and enhance clinical application potential.47 In summary, nanomedicine has shown significant potential for targeted delivery, anti-inflammatory and antioxidant therapy in renal ischemia-reperfusion injury, and can effectively improve the problems of large toxic side effects and limited effects of traditional drugs. However, its clinical transformation still faces multiple practical bottlenecks: most of the existing RIRI animal models are simple injury models, lacking the simulation of gender, age, diabetes, hypertension and other clinical comorbidities, which deviate from the pathological characteristics of real patients. The nano-drug delivery system has potential biological toxicity and is affected by excessive liver retention and individual differences, resulting in insufficient targeting stability and in vivo safety. The design of long circulation and renal clearance carriers has become a key direction for optimizing its metabolism and biocompatibility. At the level of delivery strategy, passive targeting, active targeting, and microenvironment responsive functional modification can synergistically achieve renal tissue enrichment, precise localization, and intelligent drug release of nanocarriers, constructing an integrated targeted drug release and metabolism delivery system. In the future, it is necessary to further optimize the construction of animal models to fit clinical pathological characteristics, improve the safe design and targeted modification strategies of nanocarriers, break through the core challenges of delivery efficiency, biocompatibility, and clinical translation, and promote the clinical landing of nanomedicine in the field of RIRI precision therapy.